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ABSTRACT OF CAPSTONE

MALIGNANT MELANOMA IN KENTUCKY: AN ANALYSIS OF
INDIVIDUAL AND SOCIAL FACTORS ON DISEASE STAGE AND
TREATMENT
Introduction: In 2016 there will be an estimated 76,380 new cases of malignant
melanoma and 10,130 deaths in the United States (US). 1 Malignant melanoma
incidence is increasing faster than any other preventable cancer in the US with
an expected 112,000 new cases a year by 2030. 2,3 This capstone attempts to
quantify the association of individual and social factors on melanoma late-stage
diagnosis and non-adherence to surgical treatment guidelines for early-stage
lesions in Kentucky.
Methods: The analysis combines three datasets: individual level data from the
Kentucky Cancer Registry, census tract level data from the US Census and
county level physician licensure data from the Kentucky Department of Public
Health. Descriptive statistics, univariate and multivariate logistic regression
analyses were completed.
Results: The first paper hypothesized that late-stage diagnosis is associated
with an increase in poverty level, decrease in education level and decrease in
physician density. An association between these variables of interest were not
found, rather, this study supports previous research that there is decreased odds
of late-stage diagnosis if female, married and carry private insurance.

65,123,125

The second paper hypothesized that non-standard treatment more frequently
occurs in rural and Appalachian regions and geographic areas with lower
physician density and lower socioeconomic status as indicated by an increase in
poverty level and decrease in education level. An association between nonstandard treatment and Appalachian geography, poverty level and physician
density was found. Non-standard treatment was provided to 40% of early-stage
cases and this rate is rising.
Conclusions: Kentucky is a rural state with high poverty, lower than average
education levels and low physician density but it appears that these factors have
not impacted melanoma stage of diagnosis. Instead, policy implementation
should focus on the need to increase patient access to melanoma care and
educating clinicians to halt the trend of increasing non-standard melanoma
surgical treatment for early-stage lesions in the Commonwealth.

KEYWORDS: malignant melanoma; stage of diagnosis; socioeconomic
status; Appalachian; treatment guidelines
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CHAPTER I
Introduction
In 2016 there will be an estimated 76,380 new cases of malignant
melanoma and 10,130 deaths in the United States (US). 1 Malignant melanoma
(here forward referred to as melanoma) incidence is increasing faster than any
other preventable cancer in the US with an expected 112,000 new cases a year
by 2030. 2,3 This is a public health concern because as rates steadily rise there is
no universal screening recommendation. 4,5
Melanoma is an intriguing disease; unlike other forms of cancer the
incidence occurs in a positive social gradient, where those with a higher
socioeconomic status (SES) have the highest incidence. Meanwhile those with
low SES have higher rates of late-stage disease and higher mortality rates.6
These findings have led to an interest in further delineating the characteristics of
those people who have melanoma by disease stage and how their disease is
treated.
As more than 90% of all US melanoma lesions develop in non-Hispanic
whites, Kentucky makes an interesting place to study this disease because 89%
of the population is white with an above average poverty rate of 19%. 7,8
Kentucky also has a higher rate of melanoma compared to the US with a survey
noting that some counties such as Russell and Warren ranking among the
highest in the country. 9 Additionally, as the increasing mortality rate from
melanoma leveled off in the US in the late 1980s the level has continued to rise
in Kentucky. 10 There may be several factors, individual and/or social, in
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Kentucky that are impacting melanoma incidence and mortality as the
Commonwealth has a higher proportion of the population which is generally
impoverished, rural, and medically underserved compared to other states. 8,11,12
Studies have shown that melanoma disease stage and treatment is
influenced by both individual and social factors. These factors include age,
gender, race, ultraviolet radiation (UVR) exposure, SES, marital status,
geographic location, tumor histology, tumor location, insurance status, access to
health care, and prevention efforts of sun-protective behaviors, risk awareness
and early detection efforts. 7,13-25 Additionally, the stage of diagnosis and
receiving appropriate treatment for that stage directly impacts melanoma
survival. 26,27 Despite specific treatment guidelines from the National
Comprehensive Cancer Network (NCCN) the evidence suggests that these
melanoma surgical guidelines are not followed half of the time.

28

Purpose of the study
The purpose of this capstone is to understand the variables leading to
late-stage disease diagnosis and the high mortality rate in Kentucky. This will be
done through a logistic regression analysis of individual and social factors on
melanoma stage of diagnosis and surgical treatment provided.
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Figure 1.1, Flow Diagram of Malignant Melanoma and Individual and
Social Factors with Possible Association with Disease Stage and Treatment

Melanoma

Individual Factors

• Disease stage
• Surgical Treatment

• Age
• Gender
• Marital Status
• Year of diagnosis
• Anatomic site
• Insurance status

Social Factors

• Poverty
• Education
• Urban vs Rural
geography
• Appalachian
geography
• Physician
population ratio

This capstone will include two papers, which will quantify the association
of individual and social factors on melanoma late-stage diagnosis and nonadherence to surgical treatment guidelines for early-stage lesions in Kentucky.
Refer to figure 1.1. The hope is that by determining the factors that are attributing
to late-stage diagnosis and surgical treatment guideline non-adherence for earlystage lesions that an area for direct public health intervention will be uncovered.
Paper one will describe the incidence and mortality rates of malignant melanoma
in white non-Hispanic Kentuckians from 1995 to 2013. Then the association of
individual and social variables (age, gender, marital status, year of diagnosis,
anatomical site of lesion, health insurance status, urban/rural geography,
Appalachian/non-Appalachian geography, poverty level, education level and
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physician population ratio) on incidence rates of all cases, early-stage and latestage melanoma, in white non-Hispanic Kentuckians from 1995 to 2013 will be
quantified.
Paper two will report the percentage of cases with early-stage disease that
did not adhere to the standard of care treatment, defined as clear margins, in
white non-Hispanic Kentuckians from 1995 to 2013. Then the association of
individual and social variables (age, gender, marital status, year of diagnosis,
anatomical site of lesion, health insurance status, urban/rural geography,
Appalachian/non-Appalachian geography, poverty level, education level and
physician population ratio) on the treatment provided to early-stage melanoma
cases in white non-Hispanic Kentuckians from 1995 to 2013 will be quantified.
The high poverty rate combined with the high incidence and mortality rates of
melanoma in Kentucky make this an interesting study. This study is relevant due
to the continued rise in melanoma incidence with no clear public health solution.
While most studies have looked at melanoma by analyzing a few variables, this
study attempts to analyze both individual and social determinants. The analysis
combines three datasets: individual level data from the Kentucky Cancer Registry
(KCR), census tract level data from the US Census and county level physician
licensure data from the Kentucky Department of Public Health.
Limitations, Delimitations, Innovations
There are some important limitations to this proposal. First, there is the
utilization of community level variables for SES as individual level variables are
not available. The contextual variables of poverty and education for SES will be
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utilized to understand the impact of the community on melanoma stage of
diagnosis and treatment. The use of aggregate measures for SES has been
validated but both poverty and education contextual variables represent
community level data and not individual level data. 29-31 Also, physician
population ratio is used as an aggregate to evaluate health care access but we
cannot know the amount of services used by the patients individually. This data
is cross sectional from 2006 and may not fully represent the small variation in the
physician workforce from 1995 to 2013. Additionally, this data did not account for
other medical providers including physician assistants and nurse practitioners. To
provide more accurate individual representation of the community level variables
of poverty, education and physician density this data was provided at the county
level in a state with 120 counties. Future research may better capture community
level characteristics by analysis with larger geographic regions. Although this
study analyzes multiple variables, melanoma subtypes are not included so the
effect of this variable cannot be investigated in this study. Lastly, this study is
restricted to melanoma cases in Kentucky and may not be representative of other
forms of skin cancer or other regions of the country.
Several delimitations have been placed on this study. As the majority of the
population in Kentucky is white non-Hispanics this will be the population studied.
Therefore, the effect of race on both disease stage and treatment cannot be
determined. Also, due to the low mortality rate the variables impacting survival
will not be studied. Lastly, with the changes in the standard of care for surgical
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and chemotherapy treatment during the time period of study, this study will only
analyze surgical treatment via clear surgical margins of localized disease.
This study also offers several innovations. This analysis will be the first to
provide insight into the high melanoma incidence and mortality rate in Kentucky.
The study population offers an opportunity to study previously investigated
factors in a rural, impoverished and lowered educated state. This analysis will
also be the first to provide a regression analysis looking at individual and social
determinants of non-adherence to melanoma surgical treatment guidelines in
Kentucky. Additionally, this study design provides a novel methodology by
evaluating if the melanoma NCCN guidelines for surgical treatment were followed
in a mostly rural and Appalachian population. This evaluation of individual and
social determinants will lend needed insight into the complexity of providing the
standard of care surgical treatment for melanoma. The purpose of this capstone
is to help guide future public health interventions for melanoma in Kentucky.
This capstone will be divided by chapters and include two separate papers
with background, methods, results and discussion sections that examine two
distinct facets of melanoma as described above. Chapter two will begin with a
comprehensive literature review of melanoma pathophysiology, staging,
treatment, incidence, prevalence, mortality, risk factors, prevention and screening
recommendations. This will be followed by a detailed account of the variables
that have been found to influence disease stage and surgical treatment.
Following the literature review, chapter three will contain paper one which is an
analysis of the individual and social variables associated with late-stage
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melanoma diagnosis in the Commonwealth. Chapter four will then include paper
two which is an analysis of the individual and social variables associated with
non-adherence to surgical treatment provided for early-stage melanoma. Lastly,
chapter five will summarize the capstone by providing further conclusions and
recommendations.
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CHAPTER 2

Literature review
This chapter is a literature review of melanoma pathophysiology, staging,
treatment, incidence, prevalence, mortality, risk factors, prevention and screening
recommendations. This will be followed by a comprehensive review of the
literature on variables that have been shown to effect melanoma stage of
diagnosis and adherence to surgical treatment guidelines. This review
comprises the most recent and relevant research regarding melanoma. The
works cited were gathered from presentations, books and peer reviewed
journals. The databases used were PubMed, Scopus, Embase, Tripp,
UpToDate, and MedlinePlus. Key word searches included melanoma, disease
stage, treatment, treatment guidelines, incidence, mortality, socioeconomic
status, poverty, education, Kentucky, and Appalachian region. Further review of
the literature encompassed reviewing the US and European treatment
guidelines, referencing bibliographies of seminal articles as well as those
recommended by experts and colleagues.
Pathophysiology, Staging and Treatment
The largest human organ is the skin and it is the first line of protection for
the human body. 32 The epidermis is the thin most superior layer of the skin and
keratinocytes that provide a physicochemical barrier are the most abundant cell
within the epidermis. Melanocytes are the only source of pigment in the skin and
are found in both the epidermis and dermis. 33 Melanocytes can form malignant
8

melanoma or benign skin lesions such as moles or spitz nevus. 23,34
Keratinocytes contain most of the melanin in the skin and act as a natural
sunscreen to protect the skin against ultraviolet radiation (UVR). 33 UVR
sensitivity and skin complexion are determined by the amount and type of
epidermal melanin. There are two types of melanin: eumelanin-- a dark pigment
expressed profusely in the skin of heavily pigmented people that is protective and
pheomelanin-- a light-colored pigment that is seen in fair-skinned people. This
difference in melanin explains why fair-skinned people experience more UVR
damage. 33
Cancer is a dysregulation of cell division in which the cell continues to
divide without limitations. Cancer cells also reproduce more rapidly and in a
disorganized fashion. 35 The common types of skin cancer are squamous cell
carcinoma, basal cell carcinoma and melanoma. Melanoma is considered a
pigmented skin cancer that is significantly more aggressive and deadly than the
other forms of skin cancer.32 The complexity of melanoma is not fully understood
yet it is now widely accepted that melanoma development occurs from interplay
of genetics and exposure to UVR radiation. 36
Continued research into UVR exposure has led to the clinical description
of subtypes cutaneous melanoma: non-chronic sun damage and chronic suninduced damage. 37 The non-chronic sun damaged lesions are noted to have a
high proportion of BRAF mutations. 38 The worldwide study of families with high
rates of melanoma has found genetic germline mutations in CDKN2A and
CDK4.39,40 Although important information, it is unlikely that these genetic
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findings play a large role in population-based melanoma. 40 Whereas, recent
findings through epigenomics, the Cancer Genome Atlas project and research
into stem cells has helped to explain the role of pathways such as mitogenactivated protein, BRAF mutation, VEGFR1, CD133 and CD34. 41 As research
works towards a full understanding of melanoma these findings have led to the
development of promising molecular targeted therapies.
Melanoma can be found on any area of the body that has melanocytes
which includes the skin, meninges, mucous membranes and eyes. 32 Melanoma
is distinctive in that it can arise anywhere on the body including the palms or
soles of the feet. 42 Also unique, melanocytes form lesions that are dark in
appearance yet not all melanoma lesions are dark. 23,42
Melanoma presents as one of four subtypes: superficial spreading,
nodular, lentigo maligna and acral lentiginous. 32 Superficial spreading is the
most common variant comprising 70% of all lesions and has a good prognosis.
These lesions are dark black to red and found on the back or in women on the
lower legs. Nodular lesions are the subtype with the worst prognosis and
comprise 15-30% of all lesions. Nodular lesions are seen anywhere on the body
with variation between black to pink lesions and have the shortest growth cycle of
any subtype. Lentigo maligna lesions comprise 10-15% of all lesions and have a
good prognosis. They appear tan brown and present on people over 70 years of
age on the sun-exposed surfaces of the skin. Acral lentiginous lesions have a
poor prognosis and are the least common subtype comprising less than 5% of all
lesions. These lesions are a brown to blue color and appear on the soles, palms,
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nail beds and mucous membranes. 32,43-45 Each type of lesion has distinct
characteristics and growth durations yet the histopathology is not considered a
distinct prognostic indicator. 32 Instead the location of the lesion affects the
outcome with those arising on the arm doing better than those on the leg, which
do better than those on the head and neck with finally those lesions on the trunk
have the worse prognosis. 46 This wide range of presentations can make both
screening and diagnosis difficult. 23,34
In 1970 Breslow noted that staging based on tumor thickness was the best
prognostic indicator for survival of melanoma and this is still true today. 26 The
deeper or thicker the lesion with spread into the dermis and subcutaneous layers
of the skin the more advanced the stage of disease. 47 Before staging a
melanoma lesion it must be classified into the tumor node metastasis (TNM)
classification system developed by the American Joint Committee on Cancer
(AJCC). 48 See Table 2.1. Important indicators for TNM classification and thus
survival include lesion thickness, mitosis, ulceration, lymph nodes involvement
with micrometastasis or macrometastasis, number of lymph nodes involved and if
metastasis is present, the site of metastasis and lactate dehydrogenase (LDH)
level. 17,18,47 The TNM classification underwent an important revision in 2009 with
the removal of the Clark level of invasion and adding the mitotic rate. 18 The
mitotic rate, or the proliferation of the melanoma lesion defined by number of
mitosis/mm2, was identified as a powerful independent predictor of survival.
Mitotic rate is second only to Breslow tumor thickness as a predictor for survival
in localized melanoma. 17,18
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Table 2.1
TNM Classification for Melanoma 48
T classification
TX
T0
Tis
T1

Lesion thickness (mm)
Primary tumor cannot be assessed
No evidence of primary tumor
Melanoma in situ
<1.0

T2

1.01-2.0

T3

2.01-4.0

T4

>4.0

N classification
NX
N0
N1

Number of lymph nodes (LN)
Regional LN cannot be assessed
0
1

N2

2-3

N3

4+ metastatic nodes, or matted nodes,
or in transit metastases/satellites with
metastatic nodes
Site
No detectable evidence
Distant skin, subcutaneous, distant LN
Lung
All other visceral sites
Any distant metastasis

M classification
M0
M1a
M1b
M1c

Ulceration Status/Mitosis
NA
NA
NA
a. Without ulceration and
mitosis < 1mm2
b. With ulceration and
mitosis < 1 mm 2
a. Without ulceration
b. With ulceration
a. Without ulceration
b. With ulceration
a. Without ulceration
b. With ulceration
Nodal Metastatic Mass
NA
NA
a. Micrometastasis*
b. Macrometastasis**
a. Micrometastasis*
b. Macrometastasis**
c. In transit
metastases/satellites
without metastatic nodes

Serum LDH
NA
Normal
Normal
Normal
Elevated

NA: not applicable; LDH: lactate dehydrogenase
*Micrometastases are diagnosed after sentinel lymph node biopsy
**Macrometastases are defined as clinically detectable nodal metastases confirmed
pathologically
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Following this classification a melanoma lesion is further sorted into stage
I through IV by the AJCC cancer-staging manual. 48 Refer to Table 2.2. For
research purposes the stages are commonly divided into early and late-stages
with early-stage including localized disease, which is defined as stage, I or II.
Late-stage includes regional disease defined as stage III and metastatic disease
defined as stage IV. 21,47,49 Less than 5% of patients are diagnosed with
metastatic disease while approximately 10% present with regional disease and
an estimated 85% present with localized disease. 47 This meticulous staging
process allows for an accurate diagnosis, treatment plan and prognosis.

Table 2.2
Melanoma Staging 48
Stage
Stage 0
Stage IA
Stage IB
Stage IIA
Stage IIB
Stage IIC
Stage IIIA
Stage IIIB

Stage IIIC

Stage IV

Tumor
Tis
T1a
T1b
T2a
T2b
T3a
T3b
T4a
T4b
T (1-4) a
T (1-4) a
T (1-4) b
T (1-4) b
T (1-4) a
T (1-4) a
T (1-4) a
T (1-4) b
T (1-4) b
T (1-4) b
Any T
Any T

Node
N0
N0
N0
N0
N0
N0
N0
N0
N0
N1a
N2a
N1a
N2a
N1b
N2b
N2c
N1b
N2b
N2c
N3
Any N
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Metastasis
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M1

Current recommendations for treatment are based on the stage of
melanoma and the ability to completely remove the lesion surgically with clear
margins. For all stages of melanoma wide local surgical excision is the primary
treatment.43,47 Although an excisional biopsy is preferred for pathology
evaluation often an incisional biopsy, superficial shave biopsy, deep scallop
shave biopsy or punch biopsy is performed. 43,50 The goal of the biopsy is to
pathologically confirm the melanoma diagnosis; whereas the goal of the wide
local excision with a margin of clear tissue is to achieve long-term control of the
disease and potentially a cure. 51 The type of biopsy technique used does not
influence patient outcome. 52 What is essential is the removal of the lesion via
wide local excision with clear margins. Inadequate margins can result in local
recurrence, metastasis and negatively impact survival. 53-55 The NCCN provides
specific guidelines for the amount of tissue around a lesion that needs to be
excised depending on the size of the lesion, referred to as the clear surgical
margin. 47 Refer to Table 2.3.

Table 2.3
Recommendations for Surgical Margins 47
Tumor Thickness

Recommended Clinical Margins

In Situ

0.5-1.0 cm

<1.0 mm

1.0 cm

1.01-2.0 mm

1-2 cm

2.01-4.0 mm

2.0 cm

> 4.0 mm

2.0 cm

14

Following the wide local excision a sentinel lymph node biopsy may then
be recommended depending on the stage of disease. The AJCC melanoma
staging committee recommendation states “that sentinel lymph node biopsy be
performed as a staging procedure in patients for whom the information will be
useful in planning subsequent treatments and follow-up regimens. Specifically,
the procedure should be discussed with (and recommended for) otherwise
healthy patients who have T2, T3 and T4 melanomas and clinically uninvolved
regional lymph nodes; the procedure should be recommended selectively for
patients with T1b melanomas”. 18 If a positive lymph node is found then complete
lymph node dissection should be completed and all additional areas of
metastasis should be surgically removed. 47 These recommendations are based
on the most current research in an area of great controversy, as it is still unclear
whether a complete lymph node dissection increases overall survival. 28,56
The effectiveness of non-surgical treatment is limited so it should not be
considered unless surgical excision is not feasible. 57 If surgical removal of the
lesion with clear margins cannot be obtained due the location of the primary
lesion or if there is metastatic disease, then systemic treatment is warranted. 47
Based on the NCCN guidelines for stage III and IV disease, additional treatment
following surgery is recommended including observation, systemic therapy with
interferon or clinical trial with a new therapy. 47
Systemic therapy options can include radiation therapy, chemotherapy
and/or immunotherapy. Previously the melanoma treatment options were
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sparse but in the last five years there have been considerable improvements with
the addition of molecular targeted therapy. 41 In 2011 the Federal Drug
Administration (FDA) approved systemic therapy with ipilimumab the only
monoclonal antibody directed at cytotoxic T-lymph antigen. 47 As approximately
half of patients with metastatic melanoma are BRAF positive the FDA approved
BRAF kinase inhibitors; vemurafenib in 2011 followed by dabrafenib and
trametinib in 2014. These drugs were all approved based on months of improved
overall and progression-free survival, but come with high-grade, adverse effects
and thus are reserved for treatment of recurrent disease. 47 Despite these
advances, chemotherapy and systemic therapy provide only modest response
rates affirming that early-stage diagnosis with wide surgical excision remains the
key to melanoma survival. 47,57,58

Incidence, Prevalence and Mortality rates
The incidence of melanoma in the US is increasing faster than any other
preventable cancer. Between 2002 and 2012 incidence has increased by 1.4%
annually with the average lifetime risk of developing melanoma at 2.1% in the US
population. 7 In 2013 the overall age adjusted melanoma incidence rate was 21.8
per 100,000 and this is expected to only increase as no primary prevention has
been implemented and from 1982 to 2010 incidence rates doubled. 3,7 The
increase in incidence is at least partially attributed to the increase in early-stage
detection and UVR exposure through recreational activities. 59 Yet, the sharpest
increase in incidence has been seen in low SES communities, where individuals
are less likely to be screened, indicating that the increase may not be simply an
16

artifact of screening. 2 In all population groups over the past few decades the
proportion of thin melanomas diagnosed has increased while thick melanomas
have decreased. This may be influencing the overall reduced mortality rates. 60,61
The prevalence of melanoma is also increasing due to the over 75,000
new cases per year and only a 10% mortality rate. In 2005 there were 723,416
people living with melanoma and in 2013 this number had risen to 1,034,460. 7
Non-Hispanic white men and women in the US carry over 95% of the burden of
disease. 62 While the incidence rate from 1982 to 2013 has risen steadily, the
mortality rate has remained stable at around 10%. 3,7,42 The overall survival rate
in the US has increased over the last twenty years from approximately 82% to
91%. 7 Generally, the 5-year survival of melanoma is over 90% with localized
disease, but if the cancer spreads into the regional lymph nodes the 5-year
survival is less than 50%, and with metastatic disease it is less than 10%.

45,47

Survival is dependent in part on the stage and subtype of melanoma followed by
the treatment provided. 27,45
Looking more specifically at stages, based on the AJCC staging database
through 2008, the 10-year survival for a stage IA lesion is 93% but only 39% for a
stage IIC lesion. 18 Additionally, a study by Ward-Peterson et al examined
185,219 melanoma cases from 1982 to 2011 and confirmed that the stage of
diagnosis had a significant impact on hazard ratio. 63 They found that localized
disease had a hazard ratio of 5.8 while regional disease had a hazard ratio of
31.5 and metastatic disease had a hazard ratio of 169.5. 63 Beyond disease
stage it is known that for localized disease survival is impacted by tumor
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thickness, ulceration, mitotic rate, site, gender and age. 54 Survival is also
negatively impacted by lymph node involvement with 5-year survival for stage
IIIA, IIIB and IIIC at 78%, 59% and 40% respectively. 18 Meanwhile, the one-year
survival of a stage IV melanoma is a dismal 62% for an M1a lesion, 53% for a
M1b lesion and 33% for a M1c lesion. In stage IV disease, an elevated serum
LDH level at time of diagnosis is a negative prognostic indicator with a 32% 1year survival rate compared to 65% in a patient with a normal serum LDH. 18
Decades of research have established that melanoma incidence and in
turn prevalence rates and often mortality rates, are also influenced by numerous
factors at the individual and social level. These include age, gender, race,
ultraviolet radiation (UVR) exposure, SES, marital status, geographic location,
tumor histology, tumor location, insurance status, access to health care, and
prevention efforts of sun-protective behaviors, risk awareness and early detection
efforts. 6,7, 14-25,64,65 The individual factors of age, gender, race and disease
subtype will be outlined here and then followed by social determinants. Later in
this chapter additional risk factors and prevention efforts will be discussed in
detail.
Age
Age is an important variable in both incidence and mortality rates.
Melanoma is predominantly found in non-Hispanic whites with the highest
incidence in males and those adults over 75 years old. 1,19,47,66,67 Over the past
few decades, incidence rates began to level off in those less than 65 while it
increased in those over 65. From 1983 to 2007, a 2-fold increase in incidence
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was seen in men aged 60 to 64, whereas in men aged 75 to 79 there was a 4fold increase. 68 This increase is mostly attributed to the growth in the geriatric
population. 25 Among the elderly, it has been found that minorities, those who are
single or widowed, have more comorbidities, reside in rural areas and
communities with less education and more poverty are especially at risk for latestage disease. 69
Meanwhile, in young women where there has been an 800% increase in
incidence from 1970 to 2009 that is attributed to risky health behaviors like
tanning. 6,70 Early-stage melanoma is seen more commonly in women less than
40 years old and more commonly in men after age 40. 16 Older people do have
poorer survival rates as those older than 70 tend to present with lesions that are
thicker, more ulcerated and have higher mitotic rates. 71 This increase in mortality
is also attributed to higher cumulative UVR exposure, later stage at diagnosis
and poor access to medical care. Meanwhile, the decrease in melanoma deaths
in those less than 65 years old is credited to early detection and improved
treatment. 62
Balch et al noted that age is an independent prognostic variable in
melanoma and may represent a decline in host mechanisms associated with
advancing age. 17 Comorbidities are often linked with age, as with increasing age
comes increasing health concerns. Studies have linked Parkinson’s disease,
immunosuppression from organ transplant and HIV infections to an increased
risk of melanoma. 72 Additionally, the variation in anatomic distribution of
melanoma is age-dependent. Older people more commonly develop head and
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neck melanomas with chronic sun exposure and have few nevi, whereas younger
people develop truncal melanomas dependent on sun exposure early in life and
have many nevi. 73
Gender
It is estimated that in 2016 approximately 46,870 men and 29,510 women
in the US will be diagnosed with melanoma. 74 In the US, melanoma is the fifth
most common cancer in men and the seventh most common cancer in women.74
Overall melanoma is more common in men with poorer survival rates than
women for all stages and in all age groups. 74,75 In 2016 it is estimated that
10,130 people will die of melanoma with 66% of these deaths occurring in
males.74 Interestingly, in the US the overall melanoma incidence ratio by gender
is age-dependent. For example, in women less than 49 years old, 1 in 206 will
develop a melanoma lesion and only 1 in 297 men will. Contrast this to women
older than 70 years old where 1 in 52 will develop a melanoma lesion while 1 in
33 men will.74
These statistics assist in explaining the finding that more than 50% of
melanoma deaths are in white men older than age fifty. 2 Also, males tend to
develop melanoma lesions on the head or neck while females develop lesions on
the extremities or torso. 25 Younger age, female gender and specific anatomic
sites, such as the upper limbs, are related to better overall survival. 45 A higher
rate in men is attributed in part to lower rates of sun protection behaviors, less
use of sunscreen and more time spent outdoors per lifetime compared to
women.3 It has also been discovered that men are less likely to seek skin
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cancer screening, report a concerning lesion or be concerned about previous sun
exposure. 4
Race
Those at highest risk for melanoma have light skin pigmentation and
blonde or red hair. 23 Thus, Caucasians account for over 90% of melanoma
cases reported in the US. 76 The incidence of melanoma both early and latestage is highest among non-Hispanic whites even when adjusting for SES. 16 Yet,
Hispanics, Asians and Blacks have higher percentages of late-stage disease. 6
Although there has not been a change in the overall mortality rate over the past
decades, there is inequity in the demographics of melanoma mortality. 6,45 For
example, the overall 5-year survival of melanoma from 2005 to 2011 was 70% for
blacks while it is 93% for whites. 65 This difference in survival is impacted mostly
by the later stage of diagnosis seen in minorities. A study of 1,690 melanoma
cases in Florida demonstrated that late-stage disease was more common in nonHispanic blacks and Hispanics at 52% and 26% compared to whites at 16%. 64
Yet, even when diagnosed with localized disease a disparity in survival is present
with 5-year survival at 86% for blacks and 97% for whites. 77 This difference in
stage of diagnosis and survival in minorities is attributed in part to the location of
the lesions (the majority of lesions are on non-exposed skin areas), decreased
suspicion by clinicians and patients and limited access to health education
resources or health care. 3,25
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Subtype
Although not as predictive as stage, the subtype of melanoma at diagnosis
contributes to the prognosis. Superficial spreading and lentigo maligna are both
favorable subtypes with 95% 5-year survival rate. 45 Meanwhile, acral lentiginous
has a poor prognosis with 5-year survival as low as 83% and is seen more
commonly in minority populations. 6,45 The most dangerous subtype is nodular
melanoma, comprising only 10% of all cases but is greater than 50% of all deep
(> 2 mm) lesions. Nodular lesions grow quickly and develop as new lesions that
are difficult to screen for because they do not following the typical asymmetry,
border irregularity, color, and diameter (ABCD) criteria. 78,79
Social Determinants
While the complex interplay of genetics and UVR exposure leads to the
development of melanoma it is apparent that the incidence rate is influenced also
by social factors. The effect of SES on melanoma incidence, disease stage and
survival is well documented in the literature but this interaction is multifaceted
and often difficult to measure. 6,80 Thus, contextual variables that have been used
as surrogates for SES including education level, unemployment rates, poverty
level, occupation type and median household income. 6 A contextual variable
summarizes the characteristics of the individuals in the group. 81 Therefore, the
contextual variable does not characterize the individual but the group as a
whole.82 This may deliver insight into the individual that is not otherwise
available and even more importantly offers community level information to
individual health outcomes. 83
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The best example of how individual and social factors are intertwined is
UVR exposure and SES. Increased UVR exposure through outdoor recreation
and leisure is a product of SES itself. It is hypothesized that affluence increases
geographic mobility as well as leisure time that is then linked to UVR exposure.
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This exposure to the sun is the only modifiable risk factor for melanoma
development. 23 UVR exposure is often a personal decision but impacted by SES
via education, occupation and geographic mobility. 6 It is unclear if SES affects
melanoma independently or if SES is a proxy for UVR exposure. 84 Regardless of
this relationship, it is known that SES continues to influence the incidence of
melanoma even when controlling for age, gender, UVR exposure and race. 6 For
example, an analysis of California data from 1988 to 2007 showed that Hispanics
of lower SES had higher risk of thick tumors and nodular melanoma than
Hispanics of higher SES indicating that SES impacts minorities as well. 2
A review of over forty research articles on the influence of SES on
melanoma by Reyes-Ortiz, Goodwin and Freeman explained that the positive
social gradient of melanoma is a confounder of genetics, UVR exposure and
increased screening. 6 Those cases of melanoma with high SES also tend to
have a genetic predisposition to skin cancer through fair skin, light hair and
propensity to get sun burns. 6 This is true in the US where over 90% of
melanoma cases occur in Caucasians. 76 Winter vacations to warm locations
and leisurely summers in the sun provide opportunities for increased UVR
exposure among people with high SES. 6,61 Also, those with affluence and
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access to health care are more likely to be screened for melanoma leading to
earlier and more frequent detection. 6
Education historically has been the most commonly used contextual
variable for SES because it is easy to measure, commonly reported and stable
throughout a lifetime. 83 To clarify the effect of education level on melanoma
diagnoses Pollitt et al surveyed 566 newly diagnosed patients. 20 Those surveyed
with lower education levels were more likely to report a belief that melanoma was
not very serious and never thinking of themselves as being at risk. Lower
education was also strongly associated with less knowledge about melanoma
detection. Patients at all education levels appeared to have relatively equal
access to health care but those without a college education were significantly
less likely to have received a clinical skin examination. People without a college
education were less likely to have talked with a physician about melanoma, been
told they were at risk of skin cancer, instructed to keep an eye on a certain mole
or instructed on how to look at their skin for signs of melanoma. Patients without
a college education were also 3.4 times more likely than college educated
patients to report competing health concerns with their melanoma diagnosis. 20
Unemployment has also been used as a contextual variable for SES and
appears to have a positive effect on melanoma rates. Counties with low
unemployment were found by Singh et al to have the highest rate of melanoma
when compared to high unemployment counties, incident ratio (IR) 30.1 and 23.1
respectively. 16 However, studies have found unemployment to be less important
than the type of occupation. There is a paradoxical relationship in which work-
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related UVR appears to lower the risk of melanoma in outdoor workers compared
to indoor workers. This may be because continual frequent exposure of sun
poses less risk for development of melanoma than the episodic infrequent,
intense exposures that may cause sunburns. 61 For example, a few studies have
noted an increase in melanoma in airline crews related to their increased
opportunity for recreational sun exposure. 86,87
It has also been noted that geographic location effects melanoma
incidence and this is thought to be due to the social aspects of topography. A
geographic location often embodies health care access, demographic factors of
the population and UVR exposure. 15,16,85 For instance, when comparing
metropolitan and rural areas in North Carolina it was noted that rural patients
were older and more likely to live in poverty. 85 When Singh et al compared
melanoma incidence between rural, urban and metropolitan areas, they found
the highest incidence for all melanoma cases in metropolitan areas (IR 30.5),
followed by urban (IR 25.4) with the lowest rate in rural areas (IR 23.2, p
<0.05).16 This trend was noted also for early-stage disease, but for late-stage
disease metropolitan and rural incidence rates were equivalent. Yet, upon
multivariable analysis, county population was not significant for melanoma
incidence. 16 Higher age specific rates of melanoma are also seen in areas of the
US with higher UVR exposure. 15 Alaska, for example, had the lowest rate of
melanoma from 2002 to 2006 with 13/100,000 cases compared to Hawaii with
62/100,000 cases. 67 Additionally, as expected, an analysis of UVR exposure in

25

the US found that both early and late-stage melanoma incidence rates were
significantly higher in counties with high UVR levels compared to low levels.
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Risk Factors, Prevention and Screening
Development of a melanoma lesion involves a complex and not wellunderstood interaction between individual and social factors. Individual factors
include the nonmodifiable risk factors of age, gender, race, genetics, family
history of melanoma, personal history of melanoma, lighter skin pigmentation,
blond or red hair, blue or green eyes, increased number of nevi and a tendency
to get sun burns. Of these risk factors, hair color and pigmented nevi are the
strongest and most consistent predictors of risk.

23 Significant

study has been

given to modifiable risk factors including smoking, diet, hair dyes, fluorescent
lighting, hormone therapy and stress, but no association with melanoma has
been found. 61,80 A meta-analysis by Jiang et al shows some studies with an
association between obesity and melanoma incidence and mortality and some
without. 80 Likely though, body mass index is playing a role in screening where
those with an increased body mass index have decreased screening behaviors.
80

To date, the single modifiable risk factor is sun or UVR exposure. 23 Intense

and intermittent sun exposure with sun burns especially before the age of fifteen
is a strong predisposing risk factor for melanoma later in life. 23 UVR exposure via
natural sunlight or artificial tanning is correlated with SES, as affluence affects
leisure time and the ability to travel to areas with higher UVR radiation.

84

Despite significant research there is incomplete evidence regarding the
nature, timing and extent of UVR exposure and its relationship to melanoma
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development. 15,23 It is acknowledged that there is a difference in melanoma
subtype based upon chronic sun exposure and non-chronic sun exposure but
this will remain a difficult area of research due to the limited ability to measure
sun exposure in a retrospective study and the lack of cohort studies due to the
rarity of melanoma cancers. 37,88 Various aspects of sun exposure have been
studied including smaller swimsuits, population migration to the equator, thinning
of the ozone layer and increased tanning bed use. 61,89 UVA and UVB exposure
are known to cause melanoma with UVB exposure coming from sun exposure
and tanning bed use. 23,61 It is known that sunburns at a young age are a risk as
is cumulative sun exposure. 25 A meta-analysis of over fifty articles on sun
exposure and melanoma risk noted that intermittent sun exposure and sunburns
are risk factors but surprisingly high occupational sun exposure is not. 88
A common form of intermittent sun exposure is tanning beds as
approximately 30 million people use tanning beds each year. 89 An analysis of US
tanning bed use found that approximately 35% of adults, 55% of university
students and 19% of adolescents have used a tanning bed. Regardless of age, it
is known that women tan more often than men. 90 Despite the tanning bed
industry insistence that tanning beds are safe, substantial evidence has indicated
an association between tanning bed use and melanoma. 23,89,91-93 The 7 to 20
year lag between UVR exposure and development of a melanoma lesion further
complicates analysis. 89,91 Despite this long time period, numerous studies have
found that a modest, yet significant increase in risk from tanning bed use. 94 The
tanning bed industry states that tanning beds emit more UVA radiation than UVB
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but the National Toxicology Program states that both UVA and UVB are
reasonably anticipated to be human carcinogens. 95 A study by Ting et al found
that women less than 45 years old with a history of tanning bed use had a threefold increased odds of melanoma compared to those women who reported never
using a tanning bed. 92 The population attributable risk of tanning bed use is 2.6%
to 9.4% of melanoma cases. 96
Primary and secondary prevention of melanoma through sun-protective
behaviors, risk awareness and early detection efforts are crucial. Sun-protective
behaviors include avoiding sun exposure and tanning beds, wearing protective
clothing and liberal use of sun screen. 23,25 The protective effect of sunscreen is
only circumstantial, but practical evidence would suggests that since UVR is a
risk factor for melanoma and sunscreen decreases UVR absorption then
melanoma would be prevented. 97,98 Teaching these protective behaviors to
children is fundamental as the risk for sunburns is most acute during early
childhood. Additionally, behavioral patterns and attitudes toward sun exposure
develop early on, determining both adolescent and adult behaviors. 23 To protect
children, the World Health Organization and the International Commission on
Non-Ionizing Radiation Protection recommend against those less than eighteen
years old from using artificial tanning devices. 99,100 In the US, California and
Vermont have been the first states to ban the use of tanning beds by people less
than eighteen years old. 101
The need for public and health care provider education regarding the risk
and recognition of melanoma lesion was acknowledged in 1985 with the
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development of the asymmetry, border irregularity, color and diameter (ABCD)
criteria. 24 The ABCD criterion describes a suspicious lesion as one that is
asymmetric, with irregular borders, has multiple colors and with a diameter
greater than 6mm. This acronym was developed to be a simple tool for both the
general population and medical community to recognize thin melanoma lesions.
The ABCD criterion has been shown to be both sensitive and specific for
melanoma. After decades of use the ABCD criteria has expanded to the ABCDE
criteria with the addition of the term, evolving. Evolving recognizes the change in
shape, size or symptoms of a lesion, which is especially important for nodular
melanomas. 24 This effort to increase awareness of the risk of melanoma has
increased screening rates and the detection of earlier stage lesions. 59,62,101
Research has shown that even a one-time instruction regarding the ABCDE
criteria can improve recognition of a melanoma lesion both in the general
population and by clinicians. 102,103 Meanwhile, an increased awareness of
melanoma was associated with both a decreased time to seek medical attention
for a suspicious lesion and thinner lesions. 104 Education of the public is important
because patients find the majority of melanoma lesions themselves although if
found by a clinician the lesion tends to be thinner. 25,105
To date, there has been no community-based randomized trial conducted
to demonstrate the decrease in mortality from screening asymptomatic persons
for melanoma. This lack of evidence is due to the low rate of melanoma mortality
and high costs associated with such a study. Thus, no recommendation for
routine population-based screening can be made and the US Preventative
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Services Task Force reports that there is insufficient evidence to recommend
regular skin checks on the general population. 4,5 Additionally, there are no
recommendations published for eye exams, oral exams or pelvic exams to
monitor for mucosa melanoma lesions. 44 Following melanoma treatment there is
also a lack of clarity on recommended long-term follow up. It is estimated that
there is an increased risk of developing a second primary melanoma of 8-10%,
yet intensive long-term follow up beyond five years is likely not cost effective. 106108

Despite the lack of evidence, the American Cancer Society recommends
that all people between the ages of twenty and forty be screened via clinical skin
assessment for melanoma. 1 At the same time, the American Academy of
Dermatology has developed a personal screening program, Body Mole Map,
recommending that patients perform skin self-assessments and record changes.
However, they do not specify the frequency of self-assessments, nor do they
specify how often clinician provided exams should be completed. 109 With the
community and clinicians receiving these mixed messages regarding screening,
it is not surprising that participation in screening is limited.
It is known that approximately 10% to 25% of the US population practice
regular skin self-examinations. 110 It is estimated that a skin assessment by a
dermatologist is 89% to 97% sensitive for melanoma diagnosis. 23 Yet, only 8%
to 21% of the population receives annual clinical skin exams. 111-113 A study by
Swetter et al noted that thinner lesions were found in people who the year before
had regularly examined their own skin, consulted a physician at least once and
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received a full body skin exam by a clinician. 105 But, interestingly in this study the
benefit of the full skin exam by a clinician was limited only to men over sixty; in
this age group there was a 4 times greater odds of a thin tumor compared to men
who did not receive a full skin exam by a clinician. 105 Meanwhile, it is known that
females and those with continuous Medicaid insurance are more likely to seek
screening and care for a concerning lesion, while at the same time race, SES,
health insurance status and access to health care all further influence screening
behaviors. 6,20,66,114 For example, in the Appalachian area of Kentucky access to
health care, limited finances and low education levels are all known barriers to
getting cancer screenings. 115
Additionally, the health care system itself also influences melanoma
screenings. Many experts argue that primary care physicians are critical to
melanoma control but others question if they have appropriate training or enough
time to conduct adequate skin exams. While only 13% of the population reports
having a dermatologist, 85% report seeing a physician within the last two
years.116 As the majority of health insurances require a referral to see a
dermatologist, this reinforces the role of the primary care provider in evaluating
suspicious lesions. 4 A meta-analysis noted that from 1987 to 2004 the number of
primary care physicians who performed full-body skin exams actually
decreased.117 Time constraints, competing comorbidities and patient
embarrassment were listed as barriers to completing full skin exams in a survey
of 1600 physicians. 104 An analysis of the National Ambulatory Medical Care
Surveys from 2005 to 2010 found that a patient was more likely to receive a skin
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examination at a primary care office if they saw a physician assistant or nurse
practitioner. 118 With such inconsistency in screening guidelines and practice it is
apparent that subsets of the population could be at risk for later stage diagnosis.
Disease Stage
The stage at which melanoma is diagnosed directly impacts prognosis and
survival. 27 Melanoma is staged by the AJCC cancer-staging manual and
classified into stages I through IV. These stages are frequently categorized into
early and late-stage with early-stage including stages I and II while late-stage
includes both regional disease, stage III, and metastatic disease, stage IV. 21,47,49
SEER data from 2009 indicated that the 5-year survival for localized, regional
and metastatic melanoma is 98%, 62% and 15% respectively. 21 Over the past
few decades there has been an increase in proportion of thin lesions diagnosed
with a corresponding decrease in thick lesions, which is likely impacting the
decreasing mortality rate. 60,61
Social factors that have been shown to influence the stage in which a
lesion is diagnosed include SES, geographic location, employment or
occupation, marital status, health insurance status, physician population ratio and
access to health care. 6,14-16,20-22 The effect of SES on melanoma is two-sided
with high SES linked to high incidence rates with early-stage disease and low
SES linked to lower incidence rates but poorer outcomes. 6,16 The positive social
gradient of melanoma disease stage is well supported in the literature via
multilevel analyses, case-control studies and surveys. 2,6,14,16,20,66,84,119 Singh et al
provided the most comprehensive review of SES with a multilevel Poisson
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regression of 130,359 melanoma cases from the 2004 to 2006 SEER data which
found higher county incidence ratios for all cases of melanoma where there is
lower poverty, a higher education level, a higher median household income and
lower unemployment. 16 Low poverty counties had a significantly higher IR of
melanoma compared to high poverty counties (IR 27.6 vs 15.9, p <0.05). 16 Also,
the incident rate for all cases was 47% lower in counties with low education
levels compared to those with higher education levels. For early-stage, late-stage
and all cases of melanoma the incidence rates were highest in counties with a
high median household income. 16
Although melanoma is unique with a positive social gradient this cancer is
similar to other cancers in that poverty level is associated with late-stage
disease. A study by Greenlee et al evaluated 2 million cancers in the US from
1997 to 2000 and melanoma had a two times increased odds of late-stage
disease when comparing the counties with the highest poverty to the lowest. 120
Hu et al who completed a spatial analysis of melanoma cases in Florida
confirming this juxtaposition where for every 1% increase in population living in
poverty they noted a 2% increase in late-stage melanoma cases. 121 A person’s
geographic location also has a social influence on disease stage with early-stage
diagnosis more common in urban areas where the counties have higher
education levels, higher incomes, less poverty and higher rates of health
insurance. 15
A study by Youl et al of 3,762 cases and 3,824 controls evaluated the
impact of SES on melanoma lesion thickness by evaluating education,

33

employment status and marital status.

122

The multinomial regression model

found the variables of not working, not married and lower education level to each
be significantly associated with an increased risk of having a thick melanoma
lesion. Additionally, not having a clinical skin examination within three years of
diagnosis was associated with a 45% increased risk of a thicker lesion. (RRR
1.45, p <0.001) 122 Education is known to influence position in society, access to
health care, access to health information and therefore health decision making.
Youl et al suggests that a clinical skin examination may be a mediator between
education and lesion thickness. 122
One factor that has been found to be protective for melanoma diagnosis
and survival is marriage or living with someone. 122,123 Van Durme et al noted a
53% increased risk of late-stage diagnosis of melanoma in unmarried people. 124
A study on people over 65 years old by Reyes-Ortiz et al described that being
single or widowed increased the risk of late-stage melanoma diagnosis and
significantly lowered survival. 19 McLaughlin, Fisher and Paskett evaluated the
effect of marital status on the stage of diagnosis of 192,014 melanoma cases
from 1973 to 2004. 21 Among men, the odds of late-stage melanoma versus
early-stage was 1.31 for widowed, 1.56 for those never married and 1.60 for
those separated or divorced. For women the odds of late-stage versus earlystage melanoma was 1.93 for widowed, 1.25 for never married and 1.57 for
divorced or separated. 21
These findings highlight the relationship between gender and marital
status revealing the protective effect of marriage for both sexes. These
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differences are considered to be due to the social support, insurance status and
prompting to access healthcare that is received from a spouse. The increase in
access to health care noted in married people could also be due to the spouse
spotting a lesion, peer pressure to seek screening or assistance from a spouse
for daycare or transportation to seek a clinical evaluation. 21
To have access to the US health care system the individual needs health
insurance coverage and the community needs an adequate health care
workforce. Having health insurance in the US allows one to afford screening and
treatment. Research has shown that having health insurance increases
screening rates, which in turn leads to an increase in measured incidence
rates.6,20,66 Analyses of those diagnosed with melanoma have shown that lack of
insurance or insurance with Medicaid or Medicare increases the risk of late-stage
diagnosis. 125 Meanwhile, a study of the primary care physician supply in Ohio
found a decrease in late-stage melanoma cases associated with an increase in
physician density but most significantly among those with insurance. 126
Roetzheim et al reviewed the supply of dermatologists and family
physicians in Florida and earlier detection of melanoma was associated with an
increase in both types of provider. 22 They establish that for each additional
dermatologist and family physician per 10,000 populations there was an
increased odds of early diagnosis by 39% and 21% respectively.
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Another

study evaluated the distance a patient would have to travel to see a clinician in
North Carolina and found that for every one-mile increase in distance there was a
0.6% increase in Breslow thickness; therefore, a ten-mile or longer drive to a
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clinician was associated with a clinically significant increase in melanoma lesion
thickness. Interestingly, there was a decrease in Breslow thickness for those
patients who drove over 120 miles to seek care, which supported previous
research showing a protective benefit for those patients who have the ability to
travel long distance to seek superior health care. 85,127
Of interest, those who resided in a county that had a dermatologist
traveled on average 8.3 miles less than those who resided in a county without a
dermatologist. This impact was seen even if the patient did not actually see the
dermatologist suggesting that the presence of a dermatologist was actually a
marker of an increase in supply of health care providers in general. 85 A positive
effect on early-stage of melanoma diagnosis is seen for increased physician
density and recent primary care physician visit. 15,116 Additionally, an increase in
dermatologist density is associated with decreased melanoma mortality. 128
These studies confirm the social and geographic barriers that then affect
melanoma disease stage.
Treatment
Surgery is the only potentially curative treatment for melanoma. Surgery
for localized disease, stages I and II, includes wide local excision of the primary
tumor and may include excision of lymph nodes. A biopsy followed by wide local
excision is critical for diagnosis, staging and disease free survival. 129 As Breslow
thickness increases overall survival decreases. A patient with a lesion less than
1mm has a greater than 85% 5-year survival, while a patient with a lesion thicker
than 4mm has less than 50% 5-year survival rate. 85 For localized disease,

36

Breslow tumor thickness, ulceration and mitotic rate predict disease outcome. 58
The NCCN provides melanoma treatment guidelines that are supported by an
abundance of clinical trials; they have determined that at least 1 cm and no more
than 2 cm of clear surgical margins is adequate treatment. 47,51,130 Refer to Table
3.1. These recommendations are considered the standard of care treatment
that should be provided to all patients unless not appropriate for a specific patient
based on their medical situation. 47 It is known that inadequate margins result in
higher rates of loco-regional metastasis but wide margins lead to increased
morbidity and a poor cosmetic outcome. 51,53 Therefore the goal of surgical
treatment is to optimize local control with potential cure while minimizing
morbidity. 51
The recommendation to provide a clear margin of 1-2 cm around a
melanoma lesion is due to the propensity of melanoma to disseminate and recur
locally. Local reoccurrence occurs in approximately 5% of cases but in lesions
larger than 4mm can occur in up to 12% of cases. 131,132 Local recurrence does
not occur only from inadequate surgical excisions but can be a manifestation of
an aggressive, ulcerative and thick primary lesion. 54,131 On average local
recurrence is seen in 10.5% of head and neck melanomas compared to only
3.8% in trunk and extremity lesions. 133 Local recurrence is usually associated
with the development of systemic metastasis and a poor prognosis of less than a
5% chance of survival at 10 years. 131
Several studies have confirmed that inadequate surgical margins are
correlated with local recurrence. 51,53,54,58,134 It is known that in head and neck
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lesions positive margins are seen in 6-21% of cases. Risk factors for positive
margins include ulceration, increased tumor thickness, recurrent tumor and
advanced age. 133 A study by Foster, Velasco and Hieken 2008 noted recurrence
of disease in 36% of patients with inadequate margins compared to 12% of those
with adequate margins. 134 However, these studies have not shown a significant
correlation between surgical margins, recurrence of disease and survival.51,53,54,58
A Cochran review by Sladden et al of five randomized control trials of wide
local excisions of primary cutaneous melanomas noted that none of the studies
showed a statistically significant difference in overall survival when comparing
narrow versus wide excisions. Of note, the study by Balch et al, which compared
narrow margins of 2 cm to wide margins of 4 cm, was used in developing the
most recent NCCN guidelines that established that a margin larger than 2 cm
does not improve patient outcomes. 54 Even with excessively wide margins of 2-4
cm, Sladden et al explained that the point estimate for overall survival favored
wide excision by a small degree (HR 1.04). 58 The inability to demonstrate the
effect of clear margins on survival is attributed to the lack of size and power of
the studies due to the low rate of local reoccurrence and even lower effect of
clear margins on melanoma specific deaths. Additionally, when local
reoccurrence does occur it does not cause metastasis that impacts survival. 51,55
As the effects of inadequate margins is still under investigation the current belief
is that inadequate margins increases the risk of local reoccurrence and therefore
may be associated with increased mortality. 53-55
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Despite the abundant effort to provide medical guidelines, research in the
United States shows that generally medical guidelines are followed only 55% to
75% of the time. 135,136 Although these guidelines were not developed for strict
adherence this low rate is surprising. More concerning is whether variation in
adhering to these guidelines is also a sign of inequity in health outcomes. Studies
have shown that this noncompliance with cancer treatment guidelines is present
for other cancers as well. For example, adherence to recommended
chemotherapy for breast, lung and colon cancers has been shown to occur more
frequently in higher SES areas. 137-139 This may be due to availability of treatment
because seventy percent of chemotherapy is provided in the outpatient setting.140
Whereas for melanoma, Reyes-Ortiz noted that younger age; marriage and SES
were independent predictors of receiving chemotherapy treatment. 141
Looking at melanoma surgical treatment, Cormier et al provided an
analysis of 1998 to 2001 SEER data on 18,499 cases of melanoma and found
that 31% of stage 1A, 40% of stage IB and II and 69% of stage III cases were
provided surgical treatment according to the NCCN guidelines. 28 An analysis by
Wasif et al of 35,126 melanoma cases from SEER data from 2004 to 2006 found
noncompliance with surgical margins in 68% of cases. Less than a 1 cm margin
was resected in 62% of T1, 44% of T2, 41% of T3 and 42% of T4 cases. 142
Wasif et al then completed an analysis of 2004 to 2008 SEER data that showed
that only 40% of the 60,194 cases underwent wide local excision with at least a 1
cm margin. 153 A community-based study of 252 clinically node negative
melanoma cases found that 87% of Tis and T1 tumors followed NCCN treatment
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guidelines while only 60% of T2-T4 tumors were compliant. 143 These studies
demonstrate the lack of surgical treatment adherence in melanoma. If there were
better adherence to melanoma treatment guidelines it would most likely improve
morbidity and mortality.
While there is an abundance of research on the factors that influence
melanoma incidence and mortality the research on surgical treatment adherence
is anemic. Research on the variance in surgical treatment for melanoma includes
stage of disease, anatomic site of lesion, age, race, poverty, marriage,
geography, health care system and type of health care
provider.28,53,54,85,123,129,132,143-149
The lower the stage of disease the more likely inadequate margins will be
excised revealing a bias that localized disease is less concerning. 53 Meanwhile,
numerous studies have noted that the anatomic site of a lesion, most commonly
the head and neck, plays a significant role in lesions being left with inadequate
margins. 145 This is understandable due to cosmetic concerns but this places the
patient at risk as T3 and T4 lesions most commonly have positive margins and
head and neck lesions have the poorest prognosis compared to other anatomical
sites. 54,148
The age of the patient is likely a corollary for comorbidity and has been
consistently associated with noncompliance of treatment recommendations. 142
Numerous studies have found that the risk of a patient not being provided the
recommended melanoma surgical treatment is associated with older age,
especially greater than 80 years. 28,132,142,145 One study determined that
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compared to those aged less than 35 years, patients’ aged 65 to 74 had 1.37
odds of inadequate treatment while those over 75 years had 2.38 odds. 28
Another study discovered that the odds that a doctor would not comply with
treatment guidelines increased 2.6% per life-year. 132
The effect of age on treatment is understandable but inadequate surgical
treatment of melanoma has also been associated with race. 142,146 The
multivariate analysis by Wasif et al of the 2004 to 2008 SEER data revealed that
the race of “other” had a three times greater odds of inadequate surgical margins
compared to the white race group. Also, blacks had a 1.59 odds and the “other”
race group had a 2.81 odds of noncompliance with sentinel lymph node biopsy
(SLNB) recommendations compared to whites. 142 An analysis by Collins et al of
melanoma surgical treatment from 1973 to 2004 on SEER data showed that
blacks were less likely to receive any surgical treatment but more likely to
undergo amputation. 146 This analysis of over 150,000 cases also revealed that
melanoma specific and 10-year overall survival of blacks was poorer than for
whites regardless of surgical treatment. 146
The only study to date on SES and surgical treatment, Al-Qurayshi et al
analyzed 2,765 discharge records from patients who underwent skin excisions
and revealed that patients with low annual incomes were more likely to be
treated in a non-teaching, rural or low volume hospital compared to high annual
incomes. 144 At the same time, low-income patients and Medicaid patients were
more likely to be treated by a low volume surgeon. 144
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While poverty appears to negatively affect treatment, marriage seems to
have a protective effect, as those separated, divorced or widowed were less
likely to receive surgical treatment per the NCCN guidelines. 28 Place of
residence also impacts surgical treatment as a comparison of rural and urban
counties noted that those in rural counties had a 13% decreased odds of
receiving SLNB compared to those residing in urban counties. 147 A study by
Martinez et al supports this finding noting that residents in the Southern United
States are 46% less likely to receive a SLNB compared to the Western United
States. 150 State specific variations were also dramatic with 36% of Connecticut
cases and 76% of rural California cases with inadequate margins.53 Meanwhile
those residing in the state of New Mexico had an almost 4-fold increase in odds
of non-adherence to surgical treatment guidelines compared to those in the city
of San Francisco-Oakland. 28
Meanwhile, various studies show that two other variables that could add to
the discrepancy in melanoma treatment are the health system itself and the type
of health care provider. 85,143,149 There are differences in the health care provided
in small community hospitals and large medical centers. To this point, a study by
Rivard et al hypothesized that the large referral cancer center would better
adhere to the NCCN melanoma treatment guidelines. 149 They found instead a
decreased adherence to the wide local excision guidelines but better adherence
to the SLNB guidelines in the referral cancer center compared to outside the
centers. The diminished adherence to the wide local excision guidelines was
attributed to more complex cases referred to their center and outside research
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indicating that less experienced cancer centers tend to take excessive surgical
margins. Of interest, the cancer center itself did significant impact surgical
treatment provided but the overall survival was not significantly different. 149
Since melanoma treatment is provided by a wide variety of health care
providers it makes sense that this would impact the treatment given. A study of
melanoma treatment by Stitzenberg et al in North Carolina revealed that the
health care provider and their practice patterns influenced the treatment offered,
which may influence patient outcomes. 85 Particularly, they noted that surgeons
affiliated with multidisciplinary melanoma programs were more likely to provide
sentinel lymphadenectomy while those affiliated with academic centers were
most likely to have access to clinical trials. 85 Another study evaluated the
treatment provided at one community teaching hospital and despite easily
accessible standards, physician education seminars and weekly multidisciplinary
tumor board conferences there was a wide variation in melanoma treatment. 143
Specifically, compliance with the NCCN guidelines for surgical margins was
dramatically different between non-surgical oncologist and surgical oncologist,
with 95% and 38% respectively. 143 These studies demonstrate that a wide
variety of intentional and unintentional factors may be influencing melanoma
surgical treatment.
Conclusion
As the rate of melanoma continues to rise there is an urgent need to better
understand the risk factors, individual and social that define the population most
at risk. This literature review demonstrates that those diagnosed with late-stage
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melanoma are likely a vulnerable sub-population. Additionally, this literature
review highlights inequity in health care delivery that needs further clarification.
This captstone hopes to add to the literature on the social determinants of health
that may be impacting late-stage disease diagnosis and non-adherence to
surgical treatment guidelines. The purpose of this capstone is to help guide
further public health interventions for melanoma in Kentucky.
This concludes the comprehensive literature review of melanoma
pathophysiology, staging, treatment, incidence, prevalence, mortality, risk
factors, prevention, screening recommendations and discussion of the factors
that have been shown to effect melanoma stage of diagnosis and adherence to
surgical treatment guidelines. The following two chapters will encompass paper
one which analyzes the factors influencing diagnosis of late-stage melanoma and
paper two which analyzes the factors influencing non-adherence to melanoma
surgical treatment guidelines for early-stage lesions.
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Chapter III
Individual and Social Factors Associated with Late-Stage Melanoma
Diagnosis in Kentucky

Introduction
Malignant melanoma is the most deadly form of skin cancer, yet it still has
a good prognosis with a 90% survival rate. 32,45 This high survival rate is because
85% of melanoma lesions are diagnosed at an early-stage. The 5-year survival
rate for localized, regional and metastatic melanoma is 98%, 62% and 17.9%
respectively. 7 Over the last few decades the incidence of melanoma has steadily
risen. The age-adjusted incidence rate of melanoma in the US is 21.8 cases per
100,000 population while the age-adjusted mortality rate is 2.7 per 100,000. 7
Meanwhile, in Kentucky the age-adjusted incidence rate of melanoma is 24.3
cases per 100,000 population while the age-adjusted mortality rate is 3.4 per
100,000. 7
Unlike other forms of cancer, melanoma is most likely to occur in those
with a higher socioeconomic status (SES) and generally is considered a disease
of wealthy white individuals. 6 Despite this, it is known that people with lower
SES, regardless of race, are more commonly diagnosed with an advanced
disease stage. 6 Also, earlier detection of melanoma lesions has been
associated with physician density of both family physicians and dermatologists. 22
Due to these disparities, it is important to determine how the characteristics differ
between those diagnosed with early-stage and late-stage melanoma.
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The best indicator for melanoma survival is the stage in which the lesion is
diagnosed. 26 Melanoma is staged first by determining the size of the lesion,
extent of lymph node involvement and if the tumor has metastasized. 47 Using
this information, the American Joint Committee on Cancer (AJCC) staging
manual then categorizes the lesion into stage I through IV. 48 Often these stages
are further merged into early (stage I and II) and late (stage III and IV). 21 Refer to
table 3.1. The stage at which a melanoma lesion is diagnosed then determines
the treatment course and outcome of the disease. 47
The factors that influence the stage in which a melanoma lesion is
diagnosed have been an area of significant study. The literature elucidates the
influence of individual variables such as risk awareness, ultraviolet radiation
(UVR) exposure, age, gender, race, marital status, tumor histology, tumor
location and health insurance status on melanoma disease stage. 15,1719,21,23,25,74,125

Additionally, the influences of geographic region, SES and health

care access have been established. 6,15,22 SES itself and the link between SES
and individual health is difficult to measure, so surrogate measures are
utilized.6,83
Education and poverty are often used as indicators of SES as education is
usually a stable marker throughout life and poverty has been associated with
several health outcomes. 83,152 Several studies have found an association with
both low education levels and high poverty levels and late-stage melanoma
lesions. 16,121,122,152
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In addition to SES, the inability to access the US health care system is
associated with diagnoses of later stage melanoma. 125,126 Accessing the US
health care system is complex with the anemic physician workforce at the center
of the crisis. In 2015 the American Academy of Medical Colleges (AAMC)
reported that the demand for physicians continues to grow faster than the supply
leading to a projected deficit of up to 90,400 physicians by 2025. 153 The
shortage of dermatologist is expected to only continue, especially in rural areas,
as the incidence of skin cancer increases and the capacity for training programs
stagnates. 154
Kentucky is an exceptional population to study the effect of SES and
physician density on melanoma disease stage. With a majority white population,
Kentucky has an above average rate of melanoma and a high mortality rate. 155
At the same time, Kentucky has higher rate of poverty and wider variance in the
percentage of the population by county without a high school education
compared to other US states. 156 Furthermore, this rural state ranks in the bottom
one-third of states for active primary care physicians per 100,000 population. 157
The purpose of this paper is to assess for any associations between
individual and social variables and late-stage melanoma in white non-Hispanic
Kentuckians from 1995 to 2013. We hypothesize that late-stage diagnosis is
associated with an increase in poverty level, decrease in education level and
decrease in physician density. This study intends to lend insight into the high
mortality rate in the state by identifying characteristics of those diagnosed with
late-stage disease.

47

Methods
Study population and data resources
Data on individual level variables were obtained from the Kentucky Cancer
Registry (KCR) while community level variables were attained from the United
States Census Bureau and the Kentucky Department for Public Health. The KCR
is a statewide, population-based registry funded by the National Cancer
Institute’s Surveillance Epidemiology and End Results (SEER) program and the
Centers for Disease Control and Prevention’s National Program of Cancer
Registries. 158 The KCR has 99% case ascertainment and has received gold
certification from the North America Association of Central Cancer Registries
each year since formal certification was established. 159
All reported melanoma cases from non-Hispanic whites, 18 years or older
from 1995 to 2013 were collected. Only non-Hispanic whites are described in this
study due to the limited number of cases in other race groups. Cases that were in
situ lesions or non-primary tumors were excluded. This provided data on 10,109
cases including individual data on age, gender, marital status, year of diagnosis,
anatomic site of lesion, health insurance status, rural/urban, Appalachian/nonAppalachian and stage at diagnosis.
The 2000 United States Census Bureau provided county level data on
percentage with high school education and percentage below the poverty
level.8,11 The Kentucky Department of Public Health provided 2006 physician
licensure data with number of all-physicians, family practice physicians and
dermatologists, in each county. 12 To determine the physician density the number

48

of all-physicians, family physicians and dermatologists, per 10,000 population by
county was then calculated with the 2006 US Census Bureau intercensal
population estimates. 159

Outcome and Independent Variables
The outcome variable of interest is disease stage: early versus late. Stage
at diagnosis was categorized into early and late-stage with early-stage as
referent and defined as stage I and II lesions while late-stage was defined as
stage III and IV lesions.
The independent variables of main interest are poverty level, education
level and physician density. The percentage of the county below the poverty level
and percentage with a high school education are provided as continuous
variables. Physician density is evaluated with the continuous variables of allphysicians, family practice physicians and dermatologists. Total physicians was
applied as melanoma is diagnosed by many types of physicians not only family
practice physicians and dermatologists.
The year of diagnosis was categorized into five groups with 2013 to 2010,
2009 to 2007, 2006 to 2003, 2002 to 1999 and 1998 to 1995. Gender is
categorical with male and female. Age was categorized into three groups with 65
and older, 64 to 35 and 34 to 18 years. Marital status is also categorical with
married/partner, single, widow, separate/divorced and unknown. Health
insurance status was categorized where primary payor types were grouped, with
private insurance, uninsured, Medicaid, Medicare and unknown. Geographic
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region includes two measures, urban/rural and Non-Appalachian/Appalachian.
Urban is defined as Beale codes 1 through 3 while rural is defined by Beale
codes 4 through 9. Non-Appalachian is defined by counties defined as nonAppalachian. 160 Anatomic site of the lesion is categorical based upon the area of
the body.
Statistical Analysis
Descriptive statistics were used to describe the study population and the
distribution of variables for all cases, early-stage and late-stage. A graph
displaying the trend in melanoma incidence from 1995 to 2013 for early and latestage disease by year of diagnosis was made. The proportion of the study
population that died was calculated by early and late-stage disease and by
gender.
Logistic regression was used to evaluate the unadjusted associations
between each covariate and early-stage and late-stage disease groups.
Covariates include age at diagnosis, gender, marital status, year diagnosed,
anatomical site of lesion, health insurance status, urban/rural, nonAppalachian/Appalachian, poverty level, education level, and physician
population ratio for total physicians, family practice physicians and
dermatologists. The resultant estimated odds ratios (OR) and 95% confidence
interval were reported. All significant variables were assessed for interaction
effect and significant interaction terms were described and utilized in the final
model analysis.
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Multiple logistic regression was then used to formulate the final model of
those with late-stage disease. The model was first run with all covariates and
then variables were removed using backward elimination to find the model of
best fit. All reported P-values are two-tailed with statistical significance set at an
alpha level of 0.05. All analyses were conducted using SPSS version 23. 161
Results
The demographic characteristics of the study population: all cases, earlystage and late-stage disease are described in table 3.1. There are 10,109 cases
reported with 13.6% late-stage. Comparing early and late-stage disease groups,
both have similar distribution of age with the mean age of all cases at 56.9 years
with a standard deviation of 16.2 and a range of 18-102 years. The majority of
cases occur in males with 63% of late cases found in males. Almost half of all
cases, early and late-stage occur in married individuals.
The majority of all cases and early-stage cases are on the trunk and
shoulders, hips, or limbs. Whereas almost a quarter of late-stage cases are
defined as overlapping or not otherwise specified (NOS). Almost half of all cases,
early and late-stage are reported in those with private health insurance. Latestage cases are more commonly uninsured or insured with Medicaid or Medicare
compared to early-stage lesions. Those who reside in urban areas and nonAppalachian counties report the majority of all cases, early and late-stage. The
mean percentage of those living below the poverty level by county is 15.5% with
a range of 4.1- 45.0%. The mean percentage of those with a high school
education level by county is 74.5%, with a range of 49 - 87%.
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The entire state of Kentucky has 9,109 physicians with a range of 0 - 56.5
per 10,000 population in each county. There are 1,361 family practice physicians
with a range of 0 - 7.7 per 10,000 population in each county and 121
dermatologists with a range of 0 - 0.93 per 10,000 population in each county with
the majority of counties without a dermatologist. There is a mean 20.9 allphysicians per 10,000 population for late-stage cases, compared to the early
cases at 21.7. The number of family physicians and dermatologists was similar
for early and late-stage groups.
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Table 3.1: Characteristics of Melanoma Cases by Disease Stage in
Kentucky from 1995-2013
Covariates

All Stages
n (%)
10,109

Early Stage
n (%)
8,735 (86.4)

Late Stage
n (%)
1,374 (13.6)

18-34
35-64
>64

957 (9.5)
5,732 (56.7)
3,420 (33.8)

836 (9.6)
4,951 (56.7)
2,948 (33.7)

121 (8.8)
781 (56.8)
472 (34.4)

Male
Female
Marital Status
Married/Partner
Single
Widowed
Separated/Divorced
Unknown
Year Diagnosed
1995-1998
1999-2002
2003-2006
2007-2009
2010-2013
Anatomic Site
Face, Head, Neck
Trunk
Limbs, Shoulder, Hips
Overlapping, NOS
Insurance
Private insurance
Uninsured
Medicaid
Medicare
Unknown
Geography
Urban
Rural
Geography
Non-Appalachian
Appalachian

5,433 (53.7)
4,676 (46.3)

4,567 (52.3)
4,168 (47.7)

866 (63.0)
508 (37.0)

4,450 (44)
723 (7.2)
578 (5.7)
612 (6.1)
3746 (37.1)

3,803 (43.5)
568 (6.5)
495 (5.7)
463 (5.3)
3,406 (39)

647 (47.1)
155 (11.3)
117 (8.5)
115 (8.4)
340 (24.7)

1,343 (13.3)
1,638 (16.2)
2,094 (20.7)
1,998 (19.8)
3,036 (30.0)

1,165 (13.3)
1,324 (15.2)
1,845 (21.1)
1,745 (20.0)
2,656 (30.4)

178 (13.0)
314 (22.9)
249 (18.1)
253 (18.4)
380 (27.7)

1,898 (18.8)
3,542 (35)
4,328 (42.8)
341 (3.4)

1,666 (19.1)
3,157 (36.1)
3,886 (44.5)
26 (0.3)

232 (16.9)
385 (28)
442 (32.2)
315 (22.9)

4,820 (47.7)
364 (3.6)
334 (3.3)
2,997 (29.6)
1,594 (15.8)

4,175 (47.8)
260 (3.0)
233 (2.7)
2,506 (28.7)
1,561 (17.9)

645 (46.9)
104 (7.6)
101 (7.4)
491 (35.7)
33 (2.4)

5,504 (54.4)
4,605 (45.6)

4,776 (54.7)
3,959 (45.3)

728 (53.0)
646 (47.0)

7,326 (72.5)
2,783 (27.5)
Mean (SD)
15.5% (6.6%)
74.5% (9.2%)
21.6 (14.7)
3.03 (1.32)
0.29 (0.30)

6,359 (72.8)
2,376 (27.2)
Mean (SD)
15.4% (6.5%)
74.6% (9.2%)
21.7 (14.8)
3.03 (1.32)
0.29 (0.30)

967 (70.4)
407 (29.6)
Mean (SD)
16.0% (7.1%)
73.8% (9.5%)
20.9 (14.3)
3.00 (1.33)
0.27 (0.30)

Cases
Age

Gender

Poverty level
Education level
All MD per 10,000
FP MD per 10,000
Derm per 10,000

MD, medical doctor, includes all physicians including doctors of osteopathic medicine
FP, family practice; Derm, dermatologists
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Figure 3.1 demonstrates the dramatic increase in early-stage melanoma
between 1995 and 2013. The number of early-stage melanoma cases has
steadily increased with a large increase in cases from 2003 to 2006 and the
largest number of cases reported from 2010 to 2013. Further analysis of year
groups 1995 to 2002 and 2003 to 2013 did not reveal a significant difference
among these groups to explain the rise in early-stage cases. The number of latestage melanomas has also steadily increased with a bump in the number of
cases reported in 1999 to 2002 and the largest number of cases reported from
2010 to 2013. Of the 8,735 early-stage cases, 23.9% of the male and 21.6% of
the females died. Of the 1,374 late-stage cases, 68.1% of the male and 61.8% of
the females died.
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Figure 3.1: Early and Late-Stage Melanoma by Year of Diagnosis in
Kentucky from 1995-2013

The unadjusted odds ratios for late-stage melanoma are presented in
table 3.2. Surprisingly, both of the geographic region variables and age are not
significantly associated with late-stage melanoma lesions. Further analysis of
each of these variables with stratification by year of diagnosis and pair-wise
comparison again did not reveal an association. Females have a 36% (CI 0.570.72) decreased odds of late-stage melanoma compared to males. Meanwhile,
being single has a 60% (CI 1.32-1.95) increased odds of late-stage melanoma
compared to being married, whereas being separated or divorced has a 39% (CI
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1.12-1.73) increased odds and being widowed has a 46% (1.17-1.82) increased
odds. The year of diagnosis is significant only for the years of 1999-2002 having
a 55% (1.27-1.90) increased odds of late-stage melanoma compared to 19951998. Interestingly, pair-wise comparison between year groups revealed no
significant association between groups except for increased odds of late-stage
disease for 1999-2002 compared to all other year groups. Interestingly, latestage melanoma has a 18% (0.69-0.97) decreased odds for limbs, shoulder and
hips lesions while there is a 87 times increased odds with overlapping or NOS
lesions. Those people who are uninsured have a 2.59 (CI 2.03-3.30) times higher
odds of late-stage melanoma compared to those who have private insurance
while those with Medicaid have a 2.81 (CI 2.19-3.60) higher odds and those with
Medicare have a 29% (CI 1.12-1.44) higher odds.
Poverty level, education level and density of dermatologists were each
found to be significant in the univariate analysis. So, if a county had a 10%
increase in percentage of the county in poverty there would be a 10% increased
odds of late-stage melanoma. At the same time, if a county had a 10% decrease
in percentage of the county that graduated from high school there would be a
10% increased odds of late-stage melanoma. While only 23 counties out of 120
have a dermatologist at all, we found that if a county added one dermatologist
the odds of reporting a late-stage melanoma decreased by 23% (CI 0.64-0.93).
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Table 3.2: Unadjusted Odds Ratio of Late-Stage Melanoma in Kentucky
from 1995-2013.
Covariates

Late-Stage
OR (95% CI)

Late-Stage
P value

Referent
1.09 (0.89-1.34)
1.11 (0.89-1.37)

0.411
0.355

Referent
0.64 (0.57-0.72)

<0.005

Referent
1.60 (1.32-1.95)
1.39 (1.12-1.73)
1.46 (1.17-1.82)
0.59 (0.51-0.67)

<0.005
0.001
0.003
<0.005

Referent
1.55 (1.27-1.90)
0.88 (0.72-1.09)
0.95 (0.77-1.17)
0.94 (0.77-1.13)

<0.005
0.237
0.617
0.500

Referent
0.88 (0.74-1.04)
0.82 (0.69-0.97)
87.00 (57.00-132.79)

0.134
0.019
<0.005

Referent
2.59 (2.03-3.30)
2.81 (2.19-3.60)
1.29 (1.12-1.44)
0.14 (0.10-0.20)

<0.005
<0.005
<0.005
<0.005

Referent
1.07 (0.96-1.2)

0.242

Referent
1.13 (0.99-1.28)
1.01 (1.01-1.02)
0.99 (0.98-1.00)
1.0 (0.99-1.0)
0.99 (0.95-1.03)
0.77 (0.64-0.93)

0.062
0.002
0.007
0.075
0.583
0.007

Age
18-34
35-64
>64
Gender
Male
Female
Marital Status
Married/ Partner
Single
Separated/Divorced
Widowed
Unknown
Year Diagnosed
1995-1998
1999-2002
2003-2006
2007-2009
2010-2013
Anatomic Site
Face, Head, Neck
Trunk
Limbs, Shoulder, Hips
Overlapping, NOS
Insurance
Private insurance
Uninsured
Medicaid
Medicare
Unknown
Geography
Urban
Rural
Geography
Non-Appalachian
Appalachian
Poverty level
Education level
All physicians
Family practice
Dermatologist

57

Analysis for interaction effect revealed interaction between age and
gender and insurance and gender to be significant, refer to table 3.3. Females
35-64 years old and greater than 64 have 40% (CI 0.44-0.79) and 32% (CI 0.570.81) decreased odds of late-stage melanoma compared to females 18-34 years
old. At the same time, males 35-64 years old have a 42% (CI 1.05-1.93)
increased odds compared to females 18-34 years old. Also, compared to insured
females, uninsured females, those on Medicare or with unknown insurance are
all at increased odds of late-stage disease but those on Medicaid are at the
highest risk with an over 11 (CI 6.56-19.93) fold odds. Meanwhile, the men
uninsured, on Medicaid, Medicare or unknown insurance are at even higher odds
of late-stage disease compared to insured females. Particularly, men on
Medicaid are at a 20 (CI 12.26-35.38) fold increased odds and men on Medicare
are at an almost 36 (CI 20.88-61.40) fold increased odds of late-stage
melanoma.

Table 3.3: Interaction between Age and Gender and Insurance Status and
Gender for Late-Stage Melanoma in Kentucky from 1995-2013.
Female
OR (95% CI)

Male
P value

Referent
0.60 (0.44-0.79)*
0.68 (0.57-0.81)*

0.84 (0.68-1.02)
1.42 (1.05-1.93)*
1.15 (0.98-1.34)

Referent
4.61 (2.93-7.24)*
11.44 (6.56-19.93)*
7.61 (4.25-13.64)*
6.80 (4.23-10.78)*

0.64 (0.31-1.31)
7.57 (4.84-11.82)*
20.82 (12.26-35.38)*
35.80 (20.88-61.40)*
8.35 (5.32-13.09)*

Age
18-34
35-64
>64
Insurance
Private insurance
Uninsured
Medicaid
Medicare
Unknown
* Indicates P value less than 0.05
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The final model is displayed in table 3.4 and demonstrates that marital
status, year diagnosed, anatomic site and insurance*gender are associated with
late-stage melanoma. The final model explains 14.4% (Cox and Snell R square)
and 26.3% (Nagelkerke R squared) of the variance in late-stage of diagnosis. A
Hosmer-Lemeshow goodness of fit test was conducted and gave no indication of
poor model fit at the 0.05 level (p value 0.081).
In the final model single people have a 39% (CI 1.11-1.75) increased odds
of late-stage disease, widowed have a 44% (CI 1.11-1.89) increased odds and
divorced people have a 36% (CI 1.06-1.75) increased odds compared to those
who are married. As the incidence rate of melanoma increases from 1995 to
2013 the odds of late-stage diagnosis is significantly less from 2003 to 2013.
Having a lesion that is overlapping or NOS increases the odds of late-stage
disease 82 (CI 53.84-127.84) fold. Meanwhile, compared to privately insured
females, being an uninsured female increases the odds of late-stage disease
over 3 (CI 1.93-5.51) fold and being a female on Medicaid increased the odds
over 7 (CI 4.08-14.31) fold. At the same time, men are at greater odds of latestage melanoma compared to insured females with uninsured men at almost a 5
(CI 2.83-8.00) fold odds, men on Medicaid with almost a 12 (CI 6.36-21.59) fold
odds and men on Medicare with a 19 (CI 10.35-35.63) times higher odds of latestage disease compared to insured females. While the univariate analysis
showed a significant impact of poverty, education and physician density on latestage disease the adjusted regression did not show these outcome variables of
interest to be significant.
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Table 3.4: Final Model of Adjusted Odds Ratio of Late-Stage Melanoma in
Kentucky from 1995-2013.
Covariates
Marital Status
Married/Partner
Single
Widowed
Separated/Divorced
Unknown
Year Diagnosed
1995-1998
1999-2002
2003-2006
2007-2009
2010-2013
Anatomic Site
Face, Head, Neck
Trunk
Limbs, Shoulder, Hips
Overlapping, NOS
Insurance*Gender
Female Private insurance
Female Uninsured
Female Medicaid
Female Medicare
Female Unknown
Male Private insurance
Male Uninsured
Male Medicaid
Male Medicare
Male Unknown

Late-Stage
OR (95% CI)

Late-Stage
P value

Referent
1.39 (1.11-1.75)
1.44 (1.11-1.89)
1.36 (1.06-1.75)
0.73 (0.58-0.93)

0.005
0.007
0.015
0.008

Referent
1.30 (1.00-1.68)
0.66 (0.48-0.90)
0.69 (0.50-0.94)
0.69 (0.51-0.93)

0.051
0.009
0.019
0.019

Referent
0.92 (0.76-1.10)
0.90 (0.75-1.07)
82.90 (53.84-127.84)

0.343
0.231
<0.005

Referent
3.26 (1.93-5.51)
7.64 (4.08-14.31)
4.66 (2.40-9.06)
4.08 (2.38-7.00)
0.67 (0.31-1.44)
4.76 (2.83- 8.00)
11.72 (6.36- 21.59)
19.2 (10.35-35.63)
5.03 (2.98-8.48)

<0.005
<0.005
<0.005
<0.005
0.302
<0.005
<0.005
<0.005
<0.005
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Discussion
Kentucky is a rural state with high poverty, low high school education
levels and low physician density that has high melanoma incidence and mortality
rates. Despite these factors this analysis did not find strong evidence to
conclude that the stage of melanoma diagnosis is impacted by poverty,
education or physician density. Instead, this analysis supports previous research
that demonstrates that gender, marital status and health insurance status affect
stage of diagnosis--indicating the population at highest risk for late-stage
melanoma in Kentucky is unmarried males without insurance, on Medicaid or
Medicare. 65,123,125
This study found that Kentucky mirrors the US with 86.4% of lesions
diagnosed as early-stage and the incidence rate rising dramatically over the last
few decades. 7 The upswing in early-stage cases in Kentucky begins in 2003 with
no obvious explanation. In 2002 the AJCC did publish an updated staging
manual that included tumor thickness and ulceration in the T category.

17

It is

possible that this change in staging could increase the number of lesion
considered early-stage but would not account for the continued surge still seen
today. Instead, this continued increase is most likely attributed to our aging
population, increased screening, increased recreational UV exposure and
increased tanning bed use. 2,6,14,17,59,62
As expected, the majority of cases were male but the average overall age
was younger, 56.9 years, than the national average of 63 years. 7 Interestingly,
the location of the lesion remained important as lesions on the limbs, shoulders
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and hips had a slight increase in late-stage disease compared to early-stage in
the univariate analysis, but astonishingly in the final model the overlapping lesion
or lesion NOS had an 83 times higher odds of late-stage disease. The influence
of geographic region such as, rural or Appalachia residence was not associated
with a greater odds of being a late-stage case. Yet, having a spouse or partner
was clearly protective from being diagnosed with late-stage melanoma. This
supports previous research by Mandala et al that marriage is protective against
later stage melanoma with those who are widowed at particularly increased
risk.123
In a nation that does not provide affordable health care without insurance
it is not unexpected that being uninsured or having Medicaid increases the odds
of late-stage melanoma. The analysis of interaction emphasizes the importance
and complexity of insurance by noting that females and males on Medicaid are at
increased odds of late-stage diagnosis. While at the same time, males with
Medicare are at dramatically increased odds of late-stage disease compared to
females with private insurance.
Education and poverty level by county was utilized to measure the effect
of SES on late-stage melanoma. Increased poverty and decreased education
was noted to be associated with late-stage disease in the univariate analysis but
this paper did not find an association in the final model when controlling for all
other variables. Physician density by county was significant for dermatologists in
the univariate analysis but not in the final model.
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This study has several important limitations. First, poverty and education
were used as surrogates for socioeconomic status and were measured at the
county level, not the individual level. Yet, the use of aggregate measures of
socioeconomic status has been validated by other studies. 29-31 Secondly,
physician density can only be considered an aggregate of patients’ use of
medical services. The actual use of physician services by these patients may not
be reflective of the physician density. Additionally, this study did not account for
other medical providers including physician assistants and nurse practitioners.
The analysis of poverty level, education level and physician density by county in
a state with 120 counties may have been a too finite breakdown of the data.
Further research should consider analysis by larger geographic regions. Lastly,
this study was restricted to the state of Kentucky, which may not be
representative of other parts of the country.
As the rate of melanoma continues to increase, this study shows that
Kentucky needs to focus preventative health measures towards unmarried men
who do not have private insurance, especially those with Medicare. Since this
analysis did not demonstrate any influence of poverty or education at the county
level, further research needs to be conducted with individual level data.
Additionally, the effect of health insurance status on melanoma disease stage
seen in this analysis lends itself to further investigation. Of interest would be the
effect of the recent expanded health insurance access through the Affordable
Care Act that has provided over 500,000 uninsured Kentucky residents with
coverage. 162
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Kentucky is a rural state with high poverty, lower than average education
levels and low physician density but it appears that these factors have not
impacted melanoma stage of diagnosis. Instead this study supports previous
research that indicates that public health measures should focus on unmarried
men who are uninsured or on Medicaid or Medicare. 21,74,125
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Chapter IV
Individual and Social Factors Associated with Non-standard Surgical
Treatment For Early-stage Melanoma in Kentucky
Introduction
Over the last three decades the incidence of melanoma has doubled in the
United States (US) while the mortality rate has remained stable. 3 The prognosis
for melanoma is excellent with a 98% 5-year survival rate for early-stage
disease.7 Consequently, early diagnosis and complete removal of the lesion is
paramount as local recurrence is associated with the development of systemic
metastasis and a poor prognosis of less than a 5% chance of survival at 10
years. 131
As the incidence of melanoma increases the number of clinicians
providing treatment increases which makes the need for treatment guidelines
paramount. 22,128 The National Comprehensive Cancer Network (NCCN) provides
evidence-based consensus-driven guidelines by cancer type to help guide
clinicians. 163 The NCCN melanoma treatment guidelines state that the primary
and potentially curative treatment for early-stage melanoma is wide local excision
to completely remove the lesion with clear margins. 47 Clear margins are defined
as the edge or border of the tissue that is removed around a cancer that is found
to be without cancer cells by the pathologist. 164 At least 1 cm and no more than
2 cm of clear surgical margins is recommended. 47,51,130 No residual tumor is
considered the standard of care treatment that should be provided to all patients
unless not appropriate based on their unique medical situation. 47
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Despite the specific treatment guidelines from the NCCN, evidence
suggests that melanoma surgical guidelines are followed approximately half of
the time. 28 The effect of this non-standard treatment is unclear because the
association between inadequate margins and mortality has not been confirmed
but continued morbidity can be inferred because several studies have
established that inadequate surgical margins are correlated with local
recurrence.51,53,54,58,134, Therefore, the current belief is that as inadequate
margins increase the risk of local reoccurrence it may also be associated with
increased mortality. 53-55
Although each medical situation varies, this level of variation in adherence
to medical guidelines for melanoma treatment may be a symptom of inequity in
health care delivery. While there are many papers on the risk factors that
influence melanoma incidence and mortality the literature on surgical treatment is
anemic. At this time, the research indicates that those less likely to be provided
the standard of care surgical treatment have an early-stage lesion, are older,
minority race, not married, resided in rural areas and the lesion is on their head
or neck. 28,53,54,85,123,132,143,145-148
A study by Al-Quaryshi et al also noted that patients with low annual
incomes or on Medicaid were more likely to be treated by a low-volume
surgeon.144 At the same time these low-income patients were more likely to be
treated in a non-teaching, rural or low-volume hospital. 144 Additionally, an
analysis of disparities in cancer care in West Virginia noted that residing in rural
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Appalachia itself has been associated with later stage cancer diagnoses,
variance in treatment and survival. 165
Differences in melanoma treatment have also been associated with
physician specialty, where they work in the healthcare system and their practice
patterns. 85,149 Rivard et al found that when comparing the referral cancer center
to outside centers that the referral cancer center more commonly followed
surgical guidelines for sentinel lymph node biopsy but less commonly for wide
surgical excision. 149 While melanoma surgical treatment adherence has not
been linked to physician density, access to family practice physicians and
dermatologists is associated with earlier stage diagnosis while access to
dermatologists is associated with lower mortality.

22,128

Kentucky is an excellent population to study adherence of melanoma
surgical treatment guidelines because of the high rate of melanoma in the state
with a majority white population. Also, the high poverty rate, wide range in
education levels, low physician density, rural and Appalachian geography makes
this an ideal place to investigate the effect of these social determinants of health
on early-stage melanoma treatment.
The purpose of this paper is to assess for any associations between
individual and social factors on treatment provided to early-stage melanoma in
white non-Hispanic Kentuckians from 1995 to 2013. We hypothesize that nonstandard treatment more frequently occurs in rural and Appalachian regions and
geographic areas with lower physician density and lower socioeconomic status
(SES) as indicated by an increase in poverty level and decrease in education
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level. This study intends to lend insight into the factors associated with nonstandard surgical treatment for early-stage melanoma in Kentucky, which in turn
could provide an avenue for public health intervention.
Methods
Study population and data resources
The Kentucky Cancer Registry (KCR) provided data on individual level
variables while the United States Census Bureau and the Kentucky Department
of Public Health delivered the community level variables. Early-stage melanoma
cases from non-Hispanic whites, 18 years or older from 1995 to 2013 were
gathered; insitu lesions and non-primary tumors were excluded. Early-stage was
defined as stage I and stage II. Due to minimal cases in other race groups only
non-Hispanic whites were included. Cases without treatment data were excluded.
This provided data on 8,532 cases with individual data on age, gender, marital
status, year of diagnosis, anatomic site of lesion, health insurance status, and
geographic region of rural/urban and Appalachian/non-Appalachian.
The percentage of each county with high school education and
percentage below the poverty level was collected from the 2000 United States
Census Bureau. 8,11 Meanwhile, the 2006 physician licensure data with the
number of all-physicians, family practice physicians and dermatologists in each
county was provided by the Kentucky Department of Public Health. 12 Physician
density was calculated with the number of all-physicians, family physicians and
dermatologists, per 10,000 population by county using the 2006 US Census
Bureau intercensal population estimates.

159
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Outcome and Independent Variables
The outcome variable of interest--standard of care treatment--was formed
into a dichotomous variable of yes/no. Standard of care treatment was defined as
surgical margin code 0 which is no residual tumor with all margins grossly and
microscopically negative. Non-standard of care treatment was defined as surgical
margin codes 1-9 which includes residual tumor, microscopic residual tumor,
macroscopic residual tumor, margins not evaluable, no surgical removal of the
primary site and unknown. 166
The independent variables of interest are geographic region, poverty level,
education level and physician density. Geographic region is defined with two
variables: rural/urban and Appalachian/non-Appalachian. Urban is defined as
Beale codes 1 through 3 while rural is defined as Beale codes 4 through 9. NonAppalachian is defined by counties defined as non-Appalachian. 160 Poverty level
was categorized into three groups based upon the mean of 15.5% with high as
greater than 20% of population in poverty, intermediate as 10 to 20% of
population in poverty and low as less than 10% of population in poverty.
Education level was categorized into three groups with less than 70% with high
school education level defined as low education, 70 to 80% as intermediate
education, and greater than 80% as high education.
Physician density per 10,000 population per county was defined by the
following three categories: all physicians, family practice physicians and
dermatologists. All physicians was applied as melanoma is diagnosed and
treated by many types of physicians not only family practice physicians and
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dermatologists. All Kentucky physicians were categorized into three groups
based upon a mean of 21.68 physicians per 10,000 population with high
indicating greater than 25 physicians, intermediate indicating counties with 12 to
25 physicians and low for counties with less than 12 physicians. Family practice
physicians were categorized into three groups as well based on a mean of 3.03
physicians per 10,000 population with high indicating greater than 3.10
physicians, intermediate indicating 2.6 to 3.09 physicians and low indicating less
than 2.6 family practice physicians. Dermatologist were also categorized into
three groups with a mean of 0.29 physicians with high indicating greater than
0.65 dermatologists per 10,000 population, intermediate indicating 0.11 to 0.65
dermatologists and low indicating less than 0.10 dermatologists.
The year of diagnosis was categorized into five groups with 1995 to 1998,
1999 to 2002, 2003 to 2006, 2007 to 2009 and 2010 to 2013. Gender was
categorized with male and female. Age was categorized into three groups with 65
and older, 64 to 35 and 34 to 18 years. Marital status is also categorical with
married/partner, single, widow, separated/divorced and unknown. Health
insurance status was categorized by primary payor type as private insurance,
uninsured, Medicaid, Medicare and unknown. Anatomic site of the lesion was
categorized based upon the area of the body.
Statistical Analysis
Descriptive statistics were used to describe the study population and the
distribution of variables for all cases, standard treatment and non-standard
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treatment. A graph exhibiting melanoma treatment non-adherence from 1995 to
2013 was created.
Logistic regression was used to assess the unadjusted associations
between each covariate and non-standard treatment. Covariates include age at
diagnosis, gender, marital status, year diagnosed, anatomical site of lesion,
health insurance status, urban/rural, non-Appalachian/Appalachian, poverty level,
education level and physician population ratio for all-physicians, family practice
physicians and dermatologists. The resultant estimated odds ratios (OR) and
95% confidence interval were described. Each significant variable was assessed
for interaction and significant interaction terms were described. These significant
interaction terms were then utilized in the final model.
Multiple logistic regression was used to formulate the final model of the
non-standard treatment group. The model was first run with all covariates then
variables were removed using backward elimination to find the model of best fit.
All reported P values are two-tailed. Statistical significance was set at an alpha
level of .05. All analyses were conducted using SPSS version 23. 161
Results
Of the 8,532 cases, 5,099 (59.8%) were provided the recommended
standard of care treatment for their early-stage melanoma lesion, leaving 3,433
cases with non-compliant treatment. Refer to table 4.1. The mean age of all
early-stage cases is 56.8 years with a standard deviation of 16.2 years and range
of 18 to 102 years old. For both the standard treatment and non-standard
treatment groups the majority of cases were 35 to 64 years old. While most of the
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all cases group were married, 37.7% of cases had an unknown marital status.
For the non-standard treatment group the percentage of unknown marital status
rose to 44.1% while the married group comprised only 39.5% of cases.
Exploratory analysis demonstrated that unknown marital status was not
differentially distributed with other variables therefore; the variable of marital
status was not evaluated further in the analysis.
The number of early-stage cases has increased by over two-fold from
1995 to 2013. At the same time the percentage of cases that are non-standard
treatment have significantly increased compared to the standard treatment
group. The majority of lesions in the standard and non-standard treatment groups
were found on the limbs, shoulders and hips. In the standard treatment group
57.4% of cases had private insurance while in the non-standard treatment group
only 35.9% had private insurance. The standard and non-standard treatment
groups are similar with the bulk residing in urban and non-Appalachian regions.
The mean percentage of poverty level by county for all cases is 15.5%
with a standard deviation of 6.5% and range of 4.1% to 45.4%. The standard
treatment and non-standard treatment groups are similar in poverty levels with
the non-standard group having a slightly higher percentage of cases in the high
and low poverty levels. The mean percentage of high school education level by
county for all cases is 74.5% with a standard deviation of 9.2% and range of
49.2% to 86.5%. All three groups were similar with each group having greater
than 40% of cases at a high level of education.
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The state of Kentucky has 9,109 physicians, 1,361 family practice
physicians and 121 dermatologists. There is a wide range of all physicians with
zero to 56.5 per 10,000 population per county. Comparing the standard and nonstandard treatment groups the physician density is similar. Meanwhile, the
number of family practice physicians per 10,000 population per county has a
limited range of 0 to 7.7 but significant variation between the standard and nonstandard treatment groups. With the non-standard treatment group having 37.8%
of cases from counties with high family practice physician density. While the
majority of counties do not have a dermatologist, the range of dermatologists per
10,000 population is only 0 to 0.93. Comparing treatment groups there are less
non-standard treatment cases coming from counties with high dermatologist
density.
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Table 4.1, Characteristics of Melanoma Cases by Treatment in Kentucky
from 1995-2013
Covariates

All Cases

Cases
Age
18-34
35-64
>65

n (%)
8,532 (100.0)

Standard
Treatment
n (%)
5,099 (59.8)

Non-Standard
Treatment
n (%)
3,433 (40.2)

816 (9.6)
4,849 (56.8)
2,867 (33.6)

517 (10.1)
2,993 (58.7)
1,589 (31.2)

299 (8.7)
1,856 (54.1)
1,278 (37.2)

4,464 (52.3)
4,068 (47.7)

2,634 (51.7)
2,465 (48.3)

1,830 (53.3)
1,603 (46.7)

3,792 (44.4)
568 (6.7)
458 (5.4)
495 (5.8)
3,219 (37.7)

2,432 (47.7)
354 (6.9)
278 (5.5)
331 (6.5)
1,704 (33.4)

1,360 (39.6)
214 (6.2)
180 (5.2)
164 (4.8)
1,515 (44.1)

1,155 (13.5)
1,319 (15.5)
1,839 (21.6)
1,711 (20.1)
2,508 (29.4)

1,009 (19.8)
1,220 (23.9)
1,117 (21.9)
814 (16)
939 (18.4)

146 (4.3)
99 (2.9)
722 (21)
897 (26.1)
1,569 (45.7)

1,620 (19.0)
3,074 (36.0)
3,815 (44.7)
23 (0.3)

898 (17.6)
1,848 (36.2)
2,340 (45.9)
13 (0.3)

722 (21)
1,226 (35.7)
1,475 (43)
10 (0.3)

4,157 (48.7)
260 (3.0)
233 (2.7)
2,492 (29.2)
1,390 (16.3)

2,926 (57.4)
181 (3.5)
163 (3.2)
1,679 (32.9)
150 (2.9)

1,231 (35.9)
79 (2.3)
70 (2.0)
813 (23.7)
1,240 (36.1)

4,640 (54.4)
3,892 (45.6)

2,775 (54.4)
2,324 (45.6)

1,865 (54.3)
1,568 (45.7)

6,189 (72.5)
2,343 (27.5)

3,784 (74.2)
1,315 (25.8)

2,405 (70.1)
1,028 (29.9)

Gender
Male
Female
Marital Status
Married
Single
Widowed
Separated/Divorced
Unknown
Year Diagnosed
1995-1998
1999-2002
2003-2006
2007-2009
2010-2013
Anatomic Site
Face, Head, Neck
Trunk
Limbs, Shoulder, Hips
Overlapping, NOS
Insurance
Private insurance
Uninsured
Medicaid
Medicare
Unknown
Geography
Urban
Rural
Geography
Non-Appalachian
Appalachian
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Table 4.1, continued
Covariates

All Cases
n (%)

Standard
Treatment
n (%)

Non-Standard
Treatment
n (%)

1,145 (13.4)
5,804 (68.0)
1,583 (18.6)

582 (11.4)
3,590 (70.4)
927 (18.2)

563 (16.4)
2,214 (64.5)
656 (19.1)

3,608 (42.3)
2,436 (28.6)
2,488 (29.2)

2,167 (42.5)
1,470 (28.8)
1,462 (28.7)

1,441 (42.0)
966 (28.1)
1.026 (29.9)

3,092 (36.2)
2,696 (31.6)
2,744 (32.2)

1,870 (36.7)
1,579 (31.0)
1,650 (32.4)

1,222 (35.6)
1,117 (32.5)
1,094 (31.9)

2,810 (32.9)
2,860 (33.5)
2,862 (33.5)

1,511 (29.6)
1,835 (36.0)
1,753 (34.4)

1,299 (37.8)
1,025 (29.9)
1,109 (32.3)

2,230 (26.1)
2,543 (29.8)
3,759 (44.1)

1,367 (26.8)
1,465 (28.7)
2,267 (44.5)

863 (25.1)
1,078 (31.4)
1,492 (43.5)

Poverty level
Low
Intermediate
High
Education level
High
Intermediate
Low
All physicians
High
Intermediate
Low
Family practice physicians
High
Intermediate
Low
Dermatologists
High
Intermediate
Low

Figure 4.1 demonstrates the dramatic increase in the number of earlystage melanoma lesions provided non-standard treatment between 1995 and
2013. From 1995 to 2002 less than 50 cases per year received non-standard
treatment. In 2003 the number rose to 60 then jumped to 247 in 2005 and by
2012 over 400 cases received non-standard treatment.
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Figure 4.1, Number of Early-Stage Cases with Non-Standard Treatment by
Year in Kentucky from 1995-2013

Figure 4.2 shows the proportion of early-stage lesions from 1995 to 2013
that received non-standard treatment. From 1995 to 2003 less than 20% of cases
received non-standard treatment then interestingly, this proportion increased
dramatically with 48% in 2005 and 67% in 2013.
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Figure 4.2, Proportion of Early-Stage Cases with Non-Standard Treatment
by Year in Kentucky from 1995-2013

The unadjusted odds ratios for non-standard treatment compared to
standard treatment of early-stage melanoma are presented in table 4.2.
Interestingly, gender was not significant for non-standard treatment but age
greater than 64 years was found to increase the odds of non-standard treatment
by 39% (CI 1.16-1.63) compared to people aged 18 to 34. The year the
melanoma lesion was diagnosed was significant for non-standard treatment with
the odds increasing dramatically. The lesions diagnosed from 2010 to 2013 have
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an 11.55 (9.54-13.98) times increased odds of non-standard treatment compared
to the lesions diagnosed from 1995 to 1998.
The anatomical site of a melanoma lesion also significantly effects the
treatment with a lesion on the trunk, limbs, shoulders or hips with a decreased
odds of non-standard treatment compared to the face, head or neck. Insurance
status is not significant for non-standard treatment except for unknown insurance
status, which has a 19.65 (16.38-23.57) times higher odds of non-standard
treatment compared to private insurance.
Remarkably, the unadjusted variables of urban vs. rural geography,
education level and all physician density are not significantly associated with
non-standard treatment. Now, residing in Appalachia does increase the odds of
non-standard treatment by 23% (1.12-1.35) compared to residing in nonAppalachia. Yet, surprisingly the odds of non-standard treatment is less likely in
counties with higher poverty where they are 27% (0.63-0.85) less likely to receive
non-standard treatment compared to those in low poverty level counties. Also
interesting, the odds of non-standard treatment lessen as the family practice
physician density decreases. At the same time, intermediate density for
dermatologists has a 17% (1.04-1.31) increased odds of non-standard treatment
compared to high-density counties.
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Table 4.2, Unadjusted Odds Ratio of Melanoma Non-Standard Treatment
cases in Kentucky, 1995-2013
Covariates

Non-Standard Treatment
OR (95% CI)

Non-Standard
Treatment
P value

Referent
1.07 (0.92-1.25)
1.39 (1.16-1.63)

0.374
<0.005

Referent
0.94 (0.86-1.02)

0.135

Referent
0.56 (0.43-0.73)
4.47 (3.67-5.44)
7.62 (6.25-9.28)
11.55 (9.54-13.98)

<0.005
<0.005
<0.005
<0.005

Referent
0.83 (0.73-0.93)
0.78 (0.70-0.88)
0.96 (0.42-2.20)

0.002
<0.005
0.917

Referent
1.04 (0.79-1.36)
1.02 (0.77-1.36)
1.15 (1.03-1.28)
19.65 (16.38-23.57)

0.792
0.889
0.010
<0.005

Referent
1.00 (0.92-1.10)

0.930

Referent
1.23 (1.12-1.35)

<0.005

Referent
0.64 (0.56-0.72)
0.73 (0.63-0.85)

<0.005
<0.005

Referent
0.99 (0.89-1.10)
1.06 (0.95-1.17)

0.825
0.310

Age
18-34
35-64
>64
Gender
Male
Female
Year Diagnosed
1995-1998
1999-2002
2003-2006
2007-2009
2010-2013
Anatomic Site
Face, Head, Neck
Trunk
Limbs, Shoulder, Hips
Overlapping, NOS
Insurance
Private insurance
Uninsured
Medicaid
Medicare
Unknown
Geography
Urban
Rural
Geography
Non-Appalachian
Appalachian
Poverty level
Low
Intermediate
High
Education level
High
Intermediate
Low
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Table 4.2, continued
Covariates

All physicians
High
Intermediate
Low
Family practice physicians
High
Intermediate
Low
Dermatologists
High
Intermediate
Low

Non-Standard Treatment
OR (95% CI)

Non-Standard
Treatment
P value

Referent
1.08 (0.97-1.20)
1.02 (0.91-1.13)

0.140
0.787

Referent
0.65 (0.58-0.72)
0.74 (0.66-0.82)

<0.005
<0.005

Referent
1.17 (1.04-1.31)
1.04 (0.94-1.17)

0.010
0.447

Table 4.3 shows the significant interaction terms of Appalachian
geography and family practice physicians with poverty and family practice
physicians. In counties with high density of family practice physicians,
Appalachian areas have 36% (CI 0.55-0.75) lower odds of non-standard
treatment compared to non-Appalachian areas. Whereas, when comparing nonAppalachian areas low family practice physician density decreases the odds of
non-standard treatment by 33% (CI 0.58-0.77) compared to high physician
density counties. Notably, the interaction of poverty level and family practice
physicians is significant for high-density family practice physicians where high
poverty level counties have 147% (1.95-3.10) higher odds of non-standard
treatment compared to low poverty level counties.
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Table 4.3, Interaction between Geography and Family Practice Physicians
and Poverty Level and Family Practice Physicians for Non-Standard
Treatment in Kentucky from 1995-2013

Geography
Non-Appalachian
Appalachian
Poverty level
Low
Intermediate
High

FP High
OR (95% CI)

FP Intermediate
OR (95% CI)

FP Low
OR (95% CI)

Referent
0.64 (0.55-0.75)*

1.13 (0.98-1.30)
0.92 (0.77-1.10)

0.67 (0.58-0.77)*
0.92 (0.69-1.22)

Referent
1.27 (1.06-1.52)*
2.47 (1.95-3.10)*

1.17 (0.86-1.58)
0.83 (0.70-0.98)*
1.25 (0.90-1.24)

1.21 (0.98-1.51)
0.92 (0.77-1.10)
0.98 (0.77-1.24)

* Indicates P value less than 0.05
FP, family practice physician

The final model was significant for the variables of interest: Appalachian
geography, poverty level with family practice physician density and physician
density. Refer to table 4.4. The final model explains 32.1% (Cox and Snell R
square) and 43.4% (Nagelkerke R squared) of the variance in non-standard
treatment.
Early-stage melanoma lesions in those older than 64 years old are at a
40% (CI 1.09-1.79) increased odds of non-standard treatment compared to those
aged 18 to 34. Comparing the year diagnosed, from 2003 to 2013 the odds of
non-standard treatment has increased dramatically. In 2003 to 2006 there was
an almost 3 (CI 2.41-3.68) fold increase odds of non-standard therapy followed
by a 5.77 (CI 4.67-7.12) fold increase odds of non-standard therapy in 2007 to
2009 and by 2010 to 2013 there was an over 9 (CI 7.41-11.10) fold increase
odds of non-standard therapy compared to the cases in 1995 to 1998.
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Lesions on the trunk, limbs, shoulders or hips have a 29% (CI 0.61-0.83)
decreased odds of non-standard treatment compared to lesions on the face,
head or neck. Insurance through Medicare is protective against non-standard
treatment with a 24% (CI 0.63-0.91) decreased odds compared to private
insurance while unknown insurance increases the odds over 15 (CI 12.50-18.79)
fold. Demographics of the unknown insurance group are similar to all other cases
except that 94% of unknown insurance group cases also had unknown marital
status.
While controlling for all other variables in the model, Appalachian
geography and physician density are significant for non-standard treatment.
Residing in an Appalachian area increases the odds of non-standard treatment 2
(CI 1.67-2.52) fold compared to residing in non-Appalachia. Residing in a county
with low all-physician density increases the odds of non-standard treatment by
34% (CI 1.05-1.72) but surprisingly low dermatologist density decreases the odds
of non-standard treatment by 38% (CI 0.46-0.82).
The interaction between family practice physicians and poverty level
remained significant in the final model highlighting the effect of high-density
family practice physicians and poverty level. Counties with high and intermediate
poverty and high family practice physician density have a 99% (CI 1.49-2.66) and
72% (CI 1.16-2.53) increased odds of non-standard treatment compared to
counties with low poverty and low family practice physician density.
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Table 4.4, Final Model of Adjusted Odds Ratio of Melanoma Non-Standard
Treatment cases in Kentucky, 1995-2013
Covariates

Non-Standard
Treatment
OR (95% CI)

Non-Standard Treatment
P value

Age
18-34
35-64
>64
Year Diagnosed
1995-1998
1999-2002
2003-2006
2007-2009
2010-2013
Anatomic Site
Face, Head, Neck
Trunk
Limbs, Shoulder, Hips
Overlapping, NOS
Insurance
Private insurance
Uninsured
Medicaid
Medicare
Unknown
Geography
Non-Appalachian
Appalachian
All physicians
High
Intermediate
Low
Dermatologists
High
Intermediate
Low
Poverty level & FP physicians
Low poverty, high density
Low poverty, interm density
Low poverty, low density
Interm poverty, high density
Interm poverty, interm density
Interm poverty, low density
High poverty, high density
High poverty, interm density
High poverty, low density

Referent
0.99 (0.83-1.21)
1.40 (1.09-1.79)

0.988
0.009

Referent
0.47 (0.36-0.63)
2.98 (2.41-3.68)
5.77 (4.67-7.12)
9.07 (7.41-11.10)

<0.005
<0.005
<0.005
<0.005

Referent
0.71 (0.61-0.83)
0.71 (0.61-0.82)
2.23 (0.88-6.08)

<0.005
<0.005
0.090

Referent
1.00 (0.74-1.36)
0.86 (0.63-1.19)
0.76 (0.63-0.91)
15.33 (12.50-18.79)

0.981
0.360
0.004
<0.005

Referent
2.05 (1.67-2.52)

<0.005

Referent
1.24 (0.99-1.54)
1.34 (1.05-1.72)

0.057
0.017

Referent
0.58 (0.45-0.74)
0.62 (0.46-0.82)

<0.005
<0.005

Referent
0.88 (0.61-1.28)
0.99 (0.75-1.31)
1.99 (1.49-2.66)
1.11 (0.80-1.53)
1.13 (0.85-1.49)
1.72 (1.16-2.53)
1.75 (1.11-2.76)
1.25 (0.87-1.80)

0.501
0.945
<0.005
0.528
0.404
0.007
0.015
0.230

FP, family practice physician
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Discussion
This study found that 40% of early-stage melanoma lesions did not
receive the standard of care surgical treatment, which mirrors the findings from
previous studies. 28,85,142,143, While the number of melanoma cases has steadily
increased over time, it is striking that the proportion of cases receiving nonstandard surgical treatment has dramatically increased overtime from a low of
5.3% of cases in 2002 to a high of 67.3% of cases in 2013. This reinforced
previous studies that have demonstrated a trend of decreasing compliance with
wide local excision recommendations over the recent decades.130,142,143 The
cause for this is unclear but this level on non-adherence to surgical guidelines
may be a symptom of health disparities.
As expected from previous research findings, the final model found
increased odds of non-standard surgical treatment with older age and head or
neck lesions. 53 Of interest, Medicare insurance was protective against nonstandard treatment while unknown insurance had a 15 fold increased odds.
Improved collection of this variable is necessary to better understand this group.
Interestingly, residing in Appalachian itself increased the odds of nonstandard treatment. This matches research that has found an increase in nonstandard cancer treatment in Appalachia for breast, lung and prostate cancer. 167169

For example, an analysis of lung cancer treatments in West Virginia noted

non-compliant treatment in 46.5% of the cases.168
The effect of physician density is fascinating as the final model indicates
that low all-physician density increases the odds of non-standard therapy while
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low dermatologist density decreases the odds. It must be noted that there are
only 121 dermatologists in the state of Kentucky and only 21 out of 120 counties
with a dermatologist. Therefore, dermatologist density must be further studied
while the finding of increased odds for non-standard treatment associated with
low all-physician density likely holds more weight. This supports the assertion
that increasing access to health care through all physicians is critical in
melanoma care.
Earlier research has analyzed the effect of physician density on melanoma
stage of diagnosis and mortality but this is the first to evaluate treatment
adherence. 22 It must be pointed out that physician density in this study does not
indicate where each person received treatment, as it is quite possible that
patients left their county for melanoma treatment by a dermatologist or
melanoma specialist. Also, physician density can only be considered an
aggregate of patients’ use of medical services. The actual use of physician
services by these patients may not be reflective of the physician density.
Additionally, this analysis of physician density provides no insight into physician
practice patterns or the utilization of non-physician clinicians including physician
assistants and nurse practitioners.
The interaction between poverty level and family practice physicians
highlights the relationship between poverty and access to medical care. In
counties of high family practice physician density if the county also had a high
poverty level there was a significant increase in non-standard treatment
compared to low poverty counties. This demonstrates that providing physicians
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alone is not the answer to standard melanoma treatment but that poverty itself
plays a role. This reinforces other papers that have demonstrated an association
between socioeconomic status and melanoma incidence, mortality and
chemotherapy treatment. 6,20,144
Compliance with melanoma surgical guidelines is not expected to be 100% as
the patient specific needs have priority over general guidelines. Reasons for
noncompliance are many and it is likely that there are appropriate medical
reasons for non-standard surgical treatment present in several of these cases.
That being said, 40% noncompliance is high and while physician and patient
preference during treatment discussions is difficult to study this study lends some
insight into which patients may be vulnerable. This analysis defines the
vulnerable patient as one who is older than 65 years with a head or neck lesion,
and with unknown insurance status. Additionally, those residing in Appalachia, a
county with low all-physician density or a county with high or intermediate poverty
with high family practice density and high dermatologist density are susceptible.
This paper demonstrates that the incidence of non-standard treatment is
increasing in Kentucky and it is not clear who is providing this treatment. It is
known that as the incidence of melanoma increases, the care for these deadly
lesions spreads beyond dermatologists to clinicians who do not care for a large
number of melanoma patients, attend multidisciplinary conferences or receive
relevant continued medical education. 170 Previous studies have noted that
increased compliance with surgical guidelines is associated with surgeons who
care for more melanoma cases. 143,171
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To increase compliance with melanoma surgical guidelines it has been
recommended to develop metrics that record and monitor the following of
melanoma surgical guidelines nationally. 170 Since patients are often referred to a
melanoma specialist following treatment that did not follow the guidelines, Wasif
et al recommended regionalization of melanoma treatment as is done for some
other cancer types to increase compliance. 53,170 It could also be argued that
although the guidelines are published and disseminated that there needs to be a
concerted effort to better educate all clinicians especially those in Appalachia,
counties with low all-physician density or high poverty. Additionally, clinicians
need to be made aware of those patients that are at higher odds of receiving
non-standard treatment. Lastly, patient education on melanoma treatment
guidelines may empower patients in the physician-patient discussion of treatment
options.
There are limitations to this study that need to be considered when
interpreting the findings. The primary limitation is the utilization of county level
data for poverty and education that were used as surrogates for socioeconomic
status. Although, the use of aggregate measures of socioeconomic status has
been validated by other studies it still cannot replace individual level data. 29-31
Although this study utilized cancer registry data that is regarded for its quality, it
must be pointed out that the margins recorded are pathological and not clinical. It
is known that there is shrinkage of the lesion, 10-20%, following histologic
processing that would affect the recorded margin. 172 This study utilized surgery
codes with no residual tumor as the definition of standard of care to avoid this
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limitation but this effect is still possible. While this limitation is noted it would not
account for this degree of noncompliance. 53
Another limitation is the analysis of poverty level, education level and
physician density by county in a state with 120 counties. This may have been too
fine of a categorization of the data and further research should consider analysis
by larger geographic regions. Lastly, this study was restricted to the state of
Kentucky, which may not be representative of other parts of the country.
While there is vast amounts of literature on other aspects of melanoma the
literature on treatment adherence is limited. Further research should be guided
by a need to better understand the variables pertaining to both the patient and
physician in melanoma treatment decisions. Analysis of non-compliance by type
of provider could lend insight into who is less likely to follow guidelines.
Additionally, future research needs to evaluate the cost of under treatment and
how to provide the highest quality of care to the largest number of melanoma
patients.
To determine the effect of non-adherence, further analysis is needed with
long term follow up to evaluate for the effects of morbidity and mortality. For
example, over the last few decades while the incidence of melanoma has
increased in the US from 7.9 cases per 100,000 population in 1975 to 24.0 cases
in 2013, the mortality rate for melanoma has remained steady at 2.7 deaths per
100,000 population. 157 In Kentucky, the incidence of melanoma has also
increased from 22.1 cases per 100,000 population in 1995 to 24.3 cases in 2013.
However, the mortality rate has also increased from 2.5 cases per 100,000
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population in 1994 to 3.4 cases in 2013. If the Kentucky mortality rates could be
lowered to the national rates this would result in approximately 30 fewer
melanoma deaths in Kentucky per year. 157 Therefore, further research should
investigate the increasing non-compliance of surgical guidelines and the
association with this high mortality rate.
This analysis determined that 40% of early-stage melanoma lesions in
Kentucky were provided non-standard treatment and that the rate of nonstandard surgical treatment is on the rise. This is a public health concern that
needs intervention. Additionally, this study confirmed that those at increased odd
of non-standard treatment live in Appalachia, a county with low all-physician
density or a county with high poverty and high family practice physician density.
The state of Kentucky needs to implement policy that increases patient access to
melanoma care and educates clinicians to halt the trend of increasing nonstandard melanoma treatment.
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Chapter V
Conclusion
This capstone attempted to quantify the association of individual and
social factors on melanoma late-stage diagnosis and non-adherence to surgical
treatment guidelines in Kentucky. Figure 1.1, presented in Chapter 1, depicts the
variables analyzed in this capstone that could affect both disease stage of
diagnosis and surgical treatment provided. The purpose of this concluding
chapter is to summarize the findings of the preceding chapters, discuss the
implications of these studies for public health and to summarize the limitations
and recommendations. This work was intended to identify future public health
avenues to decrease late-stage diagnosis and non-adherence to melanoma
surgical treatment guidelines.
Summary of Findings
In chapter 3, the first paper hypothesized that late-stage lesions occur
more frequently in geographic areas with lower physician density and lower
socioeconomic status (SES) as indicated by an increase in poverty level and
decrease in education level. The analysis of melanoma lesions from 1995 to
2013 did not show an association between these variables of interest. Rather,
this study supports previous research that there is a decrease in odds of latestage diagnosis if female, married and carrying private insurance. 65,123,125
In both papers, county poverty levels and county high school graduation
levels were used as contextual variables to evaluate SES. These variables have
been validated to assess SES but are community level, not individual level data.
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30,31

Since this analysis did not demonstrate an association between poverty or

education at the county level, further research needs to be conducted with
individual level data.
In a state that has received recognition for the effective expansion of the
Affordable Care Act the association between private health insurance and latestage diagnosis is intriguing. Further research needs to be conducted on the
effect of providing insurance to over 500,000 uninsured Kentuckians and if
decreases the rate of late-stage melanoma diagnosis. 162
Kentucky is a rural state with high poverty, lower than average education
levels and low physician density but it appears that these factors have not
impacted melanoma stage of diagnosis. As the rate of melanoma continues to
increase, this paper finds that Kentucky needs to focus preventative health
measures towards unmarried men who are uninsured or insured with Medicaid or
Medicare.
In chapter 4, the second paper hypothesized that non-standard treatment
is associated with geographic region of both rural and Appalachia, decrease in
physician density, increase in poverty level and decrease in education level. This
analysis of early-stage melanoma lesions from 1995 to 2013 found that 40% of
these cases were provided non-standard surgical treatment. Additionally, it was
noted that the incidence of non-standard surgical treatment is actually increasing
over time.
This paper discovered an association between non-standard treatment
and the variables of interest: Appalachian geography, poverty level and physician
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density. The effect of physician density is intriguing as low all-physician density
increases the odds of non-standard therapy while low dermatologist density
decreases the odds. At the same time, in counties of high family practice
physician density if the county also had a high poverty level there was a
significant increase in non-standard treatment compared to low poverty counties.
This analysis indicates increasing physician density in general improves
adherence to melanoma surgical treatment guidelines but that increasing
specifically family practice or dermatologist density does not.
While physician and patient preference during treatment discussions is
difficult to study this study lends some insight into which patients may be
vulnerable. This includes patients older than 65 years with a head or neck lesion,
and with unknown insurance status. Additionally, those residing in Appalachia, a
county with low all-physician density or a county with high or intermediate poverty
with high family practice density and high dermatologist density are susceptible.
The specific needs of the patient have priority over general guidelines so
compliance with melanoma surgical guidelines is not expected to be 100% but
40% noncompliance is considered too high. Further research should be directed
by a desire to improve the understanding of the factors that influence melanoma
treatment decisions between the patient and physician. Policy implementation
should focus on the need to increase patient access to melanoma care while
educating clinicians to end the trend of increasing non-standard melanoma
treatment in the state. Future research should also investigate the increasing
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non-compliance of surgical guidelines and the possible association with the
stable to slightly increasing mortality rate in Kentucky.
The analyses from these two papers will be beneficial for public health
practitioners because this is the first attempt to evaluate individual and social
factors influencing disease stage and treatment of melanoma in Kentucky.
Implications for Public Health
The role of public health is to protect the health of the entire population
through assessment, policy development and assurance. Therefore, the role of
public health professionals is to assess which populations are vulnerable.
Vulnerable populations are often defined by their social determinants of health in
which the majority of a person’s health in the United States (US) is formed. The
health of a population is generally recognized by the five determinants of health;
biology and genetics, individual behavior, social environment, physical
environment and health services. 173
This capstone has attempted to define the vulnerable population by
evaluating the effects of biology, social environment and health services on
melanoma. The incidence of melanoma is increasing faster than any other
preventable cancer in the US with an expected 112,000 new cases a year by
2030. 2,3 Melanoma is a unique cancer because incidence occurs in a positive
social gradient, where those with higher SES have the highest incidence while
those with low SES have higher rates of late-stage disease and higher mortality
rates. 6
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This capstone reinforced previous papers that highlight the increased
odds of late-stage melanoma in unmarried men who are uninsured or have
Medicaid or Medicare. This draws attention to the complex interplay between
gender, social support of marriage and access to health services. As public
health professionals, our role is to direct our screening efforts toward unmarried
men without private insurance. Additionally, we must push for policy changes that
increase insurance coverage for this population.
Supporting preceding research, this capstone found that 40% of earlystage melanoma lesions do not receive the standard of care surgical treatment
and that the incidence of non-standard treatment is on the rise. 28,130,85142,143 This
disparity in melanoma treatment is a public health concern. As epidemiologists, it
is our role to bring to light the factors that are influencing a population’s health.
The healthcare community needs to be made aware of this disparity and who is
at highest risk for non-standard treatment. We must determine why those who
reside in Appalachia are twice as likely to receive non-standard surgical
treatment. At the same time, public health leaders need to implement policy that
increases patient access to melanoma care and educates clinicians to stop this
trend within the state.
Strengths and Limitations
This capstone has several strengths including that it is the first to evaluate
individual and social factors influencing disease stage and treatment of
melanoma in Kentucky. Also, due to the excellent cancer registry within the state,
this capstone analyzed over 10,000 cases, which provided a robust sample size.
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Another strength of this capstone is the novel methodology of evaluating surgical
treatment adherence for early-stage disease that had not previously been
evaluated in a mostly rural, impoverished and Appalachian population. While the
literature on melanoma incidence and mortality is strong the information on
treatment is anemic. This capstone hopes to add to this information gap.
Despite these strengths, this capstone also has limitations, presented in
chapters 3 and 4. In both papers the most notable limitation is the utilization of
surrogates for SES. Although, the use of aggregate measures of SES has been
validated by other studies it still cannot replace individual level data. 29-31 Also,
the use of physician density was used in this study and can only be considered
an aggregate of patients’ use of medical services. This data is cross sectional
from 2006 and may not fully represent the small variations in the physician
workforce from 1995 to 2013. The actual use of physician services by these
patients may not be reflective of the physician density. Additionally, this analysis
of physician density provides no insight into physician practice patterns or the
utilization of non-physician clinicians including physician assistants and nurse
practitioners.
Another important limitation is that the analysis of poverty level, education
level and physician density was done by county in a state with 120 counties and
this may be a too fine a breakdown of the data. Future research may better
capture community level characteristics with analysis of larger geographic
regions. Lastly, this study was restricted to the state of Kentucky, which may not
be representative of other parts of the country.
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Recommendations
Future research is needed to help public health researchers to disentangle
the complex relationship between individual and social factors in melanoma
diagnosis and treatment. In addition to recommendations noted above, further
research should be guided by a need to better understand the variables
pertaining to both the patient and physician in melanoma treatment decisions.
Researchers could gather more information regarding these treatment decisions
through chart review or physician and patient survey.
To improve the evaluation of physician density, it is recommended that
future research also collect data on non-physician providers who directly
diagnose and treat melanoma patients. Researchers may also be able to
address the issue of access to care through the use of GIS mapping techniques.
Over the last few decades the mortality rate for melanoma has not
improved, remaining stable nationally and slightly increasing in Kentucky. 7 To
date the association between clear margins and morality rate has not been
confirmed. 54 Researchers should initiate a study with long term follow up to
define the effect of non-adherence to treatment guidelines on morbidity and
mortality.
Lastly, in a country that has lost control of the cost of health care, future
research needs to evaluate the cost of non-standard treatment and how to
provide the highest quality of care to the largest number of melanoma patients.
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Delegates for Kentucky
2013 - 2014
President, Kentucky Academy of Physician Assistants,
• Passed state legislation to decrease co-signatures to 10%
• Increased board and membership involvement
• Began PA week statewide celebrations
2014 - Present
Member, Physician Assistant Education Association, Government
Relations and External Affairs Council (GREAC)
2014 - 2015
Past President, Kentucky Academy of Physician Assistants,
• Proposed state legislation to increase PA:MD ratio to 4:1
• Invested in larger management association
2015
Member, American Academy of Physician Assistants, House of
Delegates for Kentucky
Symposium/Meeting Chair/Coordinator
2013
Organizer & Participant, Kentucky Academy of Physician Assistants
Annual Conference, Lexington, KY
2014
Organizer & Participant, Kentucky Academy of Physician Assistants
Annual Conference, Lexington, KY
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PROFESSIONAL COMMUNITY ACTIVITIES
2002 - 2005
Registered Nurse Volunteer, Volunteers in Medicine Clinic, Volunteer
Run Primary Care Clinic, Eugene, OR
• Performed nursing duties and operated as pharmacy leader
2003
Registered Nurse Volunteer, Cascade Health Solutions, Medical
Mission to Guatemala (2 weeks)
• Performed nursing duties at inpatient hospital
2005
Registered Nurse Volunteer, Cascade Health Solutions, Medical
Mission to Guatemala (2 weeks)
• Performed nursing duties at inpatient hospital
2011 - Present
Program Coordinator, Blessings in a Backpack, Lexington, KY
• Organized volunteers, coordinated monthly food shipments and
weekly delivers to elementary school students
• Provides food to 60 children each week to supplement nutrition for
the weekend
2012
Interviewee, Louisville Business First, Interviewed and quoted for
article regarding increasing role of Physician Assistants in health
care in Kentucky
2012 - 2013
Physician Assistant, Kentucky Bone and Joint Surgeons,
• Clinical work one day a week as a PA in orthopedic clinic
2013
Interviewee, WEKU Radio, Kentucky, interviewed as the Presidentelect of Kentucky Academy of Physician Assistants
2013
Interviewee, Jessamine Journal, Interviewed and quoted for article
regarding Senator Buford's award as legislator of the year
2014
Interviewee, Kentucky Radio Stations, Radio interview regarding
2014 PA legislation, played on 114 radio stations in Kentucky
SERVICE AT PREVIOUS INSTITUTIONS
2011 - Present
Member, University of Kentucky, Advanced Practice Providers
2012 - 2015
Academic Advisor, University of Kentucky,
• Advised students throughout their PA education
• Monitored academic advancement through lock step curriculum and
met with students throughout their 28 month program to discuss their
progress.
2012
Faculty Representative, University of Kentucky College of Health
Sciences, Physician Assistant Studies
• Developed and implemented shadowing program for 60 PA
students as two campuses
2012 - 2014
Faculty Advisor, University of Kentucky, Physician Assistant
Program, Joseph Hamburg Student Society Class of 2014
• Advising position elected by PA student
• Advised/attended each monthly student board meeting
• Raised $2,000 for New Hope free clinic
2012 - Present
Member, University of Kentucky College of Health Sciences,
Physician Assistant Studies, Admissions Committee
• Developed and implemented holistic admissions with goal of
increasing diversity
2012 - Present
Member, University of Kentucky College of Health Sciences,
Physician Assistant Studies, Clinical Curriculum Committee
2012 - Present
Member, University of Kentucky College of Health Sciences,
Physician Assistant Studies, Didactic Curriculum Committee
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2012 - Present

2012
2012

2012 - Present

2012

2013

2013

2013 - Present
2013

2014

2014

2014 - Present
2015

Member, University of Kentucky College of Health Sciences,
Physician Assistant Studies, Curriculum Development Committee
• Analysis of current curriculum and development of new curriculum
proposal
Faculty Mentor, University of Kentucky College of Health Sciences,
AHEC interdisciplinary event to educate high school students about
roles in health care
Group Facilitator, University of Kentucky College of Health Sciences,
Common Reading Experience
• Read and discussed Common Reading book with interdisciplinary
students
Faculty Mentor, University of Kentucky College of Health Sciences,
• PA mentor to pre-PA students
• Individually student meetings to discuss PA profession
• Formal presentation at pre-PA club meetings
Faculty Representative, University of Kentucky College of Health
Sciences, Physician Assistant Studies
• Developed and implemented a one-day student education track at
the KAPA conference for PA students throughout the state each
noted year
• Hosted the 1st, 2nd, and 3rd annual KAPA Challenge Bowl
Faculty Representative, University of Kentucky College of Health
Sciences, Physician Assistant Studies
• Arranged PA students to participate in PA lobbying day at capitol in
Frankfort, KY
Faculty Representative, University of Kentucky College of Health
Sciences, Physician Assistant Studies
• Developed and implemented shadowing program for 60 PA
students as two campuses
Faculty Council Member, University of Kentucky College of Health
Sciences
Faculty Representative, University of Kentucky College of Health
Sciences, Physician Assistant Studies
• Developed and implemented a one-day student education track at
the KAPA conference for PA students throughout the state each
noted year
• Hosted the 1st, 2nd, and 3rd annual KAPA Challenge Bowl
Faculty Representative, University of Kentucky College of Health
Sciences, Physician Assistant Studies
• Arranged PA students to participate in PA lobbying day at capitol in
Frankfort, KY
Faculty Representative, University of Kentucky College of Health
Sciences, Physician Assistant Studies
• Developed and implemented a one-day student education track at
the KAPA conference for PA students throughout the state each
noted year
• Hosted the 1st, 2nd, and 3rd annual KAPA Challenge Bowl
Physician Assistant, University of Kentucky Medical Center, Clinical
work one day a week as internal medicine hospitalist PA
Faculty Representative, University of Kentucky College of Health
Sciences, Physician Assistant Studies
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• Arranged PA students to participate in PA lobbying day at capitol in
Frankfort, KY
MEMBERSHIPS IN PROFESSIONAL SOCIETIES
2005 - Present
Member, American Academy of Physician Assistants
2008 - Present
Member, Kentucky Academy of Physician Assistants
2012 - Present
Member, Physician Assistant Education Association
2016 - Present
Member, Utah Academy of Physician Assistants
FUNDING
09/01/13 12/31/14

OHNEP: Integrating Oral Health with Primary Care: Engaging
Students in Advanced Nursing Practice and Physician Assistant
Studies
Principal Investigator: K Skaff
Direct Costs: $2,000 Total Costs: $2,000
Oral Health Nursing Education & Practice
Role: Co-Instructor

TEACHING RESPONSIBILITIES/ASSIGNMENTS
Courses Directed
2012 - 2013
Course Director, PAS 669 Internal Medicine Clerkship, Physician
Assistant Studies, University of Kentucky
• 6 credit course, yearlong course, distance learning, 60 students
• Each student takes course for 8 weeks working in internal medicine
gaining experience in both ambulatory and hospital settings
Fall 2012
Course Director, PAS 650 Clinical Methods, Physician Assistant
Studies, University of Kentucky
• 4 credit course, 60 students on two campuses
• 3 hour lab session, three times a week
• This course is designed to teach students to perform and document
a complete history and physical exam
2013 - 2014
Course Director, PAS 663 Surgery Clerkship, Physician Assistant
Studies, University of Kentucky
• 3 credit course, yearlong course, distance learning, 60 students
• Each student takes course for 4 weeks working in surgical setting
Fall 2013
Course Director, PAS 650 Clinical Methods, Physician Assistant
Studies, University of Kentucky
• 4 credit course, 60 students on two campuses
• 3 hour lab session, three times a week
• This course is designed to teach students to perform and document
a complete history and physical exam
Spring 2014
Course Director, PAS 651 Introduction to the PA Profession,
Physician Assistant Studies, University of Kentucky
• 2 credit course, 60 students on two campuses
• This course is designed to cover health care issues for the primary
care physician assistant and is taught in module format: PA
profession for 10 weeks and ethics for 5 weeks which is taught by a
co-instructor
2014 - 2015
Course Director, PAS 669 Internal Medicine Clerkship, Physician
Assistant Studies, University of Kentucky
• 6 credit course, yearlong course, distance learning, 60 students
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Fall 2014

Spring 2015
Summer 2016
Summer 2016
Fall 2016
Fall 2016
Fall 2016

• Each student takes course for 8 weeks working in internal medicine
gaining experience in both ambulatory and hospital settings
Course Director, PAS 650 Clinical Methods, Physician Assistant
Studies, University of Kentucky
• 4 credit course, 60 students on two campuses
• 3 hour lab session, three times a week
• This course is designed to teach students to perform and document
a complete history and physical exam
Course Director, PAS 651, Introduction to the PA Profession,
Physician Assistant Studies, University of Kentucky
FPMD 6040 Introduction to Professional Issues, Physician Assistant
Studies, 48 students
FPMD 6023 Oncology Course, Physician Assistant Studies, 45
students
FPMD 6041 Professional Issues and Cultural Competency, Physician
Assistant Studies, 46 students
FPMD 6051 Evidence Based Medicine Course, Physician Assistant
Studies, 46 students
FPMD 6011 Hematology Course, Physician Assistant Studies, 45
students

Course Lectures
Nov 2011
Guest Lecturer, PAS 654: Clinical Lecture Series I, University of
Kentucky. Physician Assistant Program, Lymphoma and Multiple
Myeloma
Apr 2012
Guest Lecturer, PAS 654: Clinical Lecture Series I, University of
Kentucky, Physician Assistant Program. Lymphoma and Multiple
Myeloma
July 2012
Guest Lecturer, PAS 654: Clinical Lecture Series I, University of
Kentucky, Physician Assistant Program. Anemia, Clotting and
Bleeding disorders
Sept 2012
Guest Lecturer, PAS 657: Clinical Lab Procedures, University of
Kentucky, Physician Assistant Program. Assessment of Hemostasis
Nov 2012
Guest Lecturer, PAS 654: Clinical Lecture Series I, University of
Kentucky, Physician Assistant Program. Lymphoma and Multiple
Myeloma
Dec 2012
Guest Lecturer, MLS 460: Clinical Hematology, University of
Kentucky, Medical Laboratory Science Program. Treatment of
Leukocyte Disorders
Spring 2013
Co-Instructor, PAS 656: Patient Evaluation and Management,
University of Kentucky, Physician Assistant Studies.
• 4 credit course, 60 students on two campuses
• 3 hour lab session, meets three times a week
• Course is taught in a block format with ECG, radiology and
procedures
Mar 2013
Guest Lecturer, PAS 651: Introduction to the PA Profession,
University of Kentucky, Physician Assistant Studies. PA Advocacy
Mar 2013
Guest Lecturer, PAS 651: Introduction to the PA Profession,
University of Kentucky, Physician Assistant Program. Health Care
Inequalities
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Sept 2013
Dec 2013
Sept 2014
Sept 2014
Dec 2014
Spring 2015

Spring 2016
Summer 2016
Fall 2016

Guest Lecturer, PAS 654: Clinical Lecture Series I, University of
Kentucky, Physician Assistant Program. Anemia, Clotting and
Bleeding disorders
Guest Lecturer, MLS 460: Clinical Hematology, University of
Kentucky, Medical Laboratory Science Program. Treatment of
Leukocyte Disorders
Guest Lecturer, PAS 654: Clinical Lecture Series I, University of
Kentucky, Physician Assistant Program. Lymphoma and Multiple
Myeloma
Guest Lecturer, PAS 654: Clinical Lecture Series I, University of
Kentucky, Physician Assistant Program. Anemia, Clotting and
Bleeding disorders
Guest Lecturer, MLS 460, University of Kentucky, Clinical
Hematology, Medical Laboratory Science Program. Treatment of
Leukocyte Disorders
Co-Instructor, PAS 656: Patient Evaluation and Management,
University of Kentucky, Physician Assistant Studies.
• 4 credit course, 60 students on two campuses
• 3 hour lab session, meets three times a week
• Course is taught in a block format with ECG, radiology and
procedures
Instructor, University of Utah. FPMD 6042 Tutorial Course, Small
Group Teaching, Physician Assistant Studies, 4 students
Instructor, University of Utah. FPMD 6043 Tutorial Course, Small
Group Teaching, Physician Assistant Studies, 4 students
Instructor, University of Utah. FPMD 6041 Tutorial Course, Small
Group Teaching, Physician Assistant Studies, 4 students

Small Group Teaching
May 2012
Small Group Facilitator, PAS 610 Research Methods, Physician
Assistant Program, University of Kentucky
May 2012
Small Group Facilitator, CNU 503 Applied Nutrition, Physician
Assistant Program, University of Kentucky
June 2014 Small Group Facilitator, iCats Year 1, Inter-professional education
Present
program, University of Kentucky
• Member of IPE program development
• 2 year curriculum of IPE education including PA, PT, RN and
PharmD students
Trainee Supervision
Masters
2013 - 2014
Research Supervisor, Brittany Cianelli, Physician Assistant Program,
University of Kentucky. Pain Crisis of Pediatric Sickle Cell Patients
Adversely Affects Quality of Life
Educational Lectures
Department/Division Conferences
2013
PA Advocacy, PA Program Orientation, Physician Assistant Program,
University of Kentucky
2013
Physician Assistants Legislation Update, University of Kentucky
Advanced Practice Providers Quarterly Meeting
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2013
2013
2014
2014

PA Advocacy, PA Program Orientation, Physician Assistant Program,
University of Kentucky
Kentucky Physician Assistants in the future health care system,
Allied Health Week, University of Kentucky College of Health
Sciences
Physician Assistants Legislation Update, University of Kentucky
Advanced Practice Providers Quarterly Meeting
PA Advocacy, PA Program Orientation, Physician Assistant Program,
University of Kentucky

Continuing Education
CE Courses Taught
2016
Faculty Skills 101 PANDO Workshop, Physician Assistant Educators,
30 participants, 15 hours CME
PEER-REVIEWED JOURNAL ARTICLES
1. Coombs J, Valentin VL (2014). Salary Differences of Male and Female PA
Educators. Journal of Physician Assistant Education.
2. Valentin VL, Dehn RW, Baker MD (2016). Commentaries on health services
research. JAAPA, 29(2), 1-2.
3. Morgan P, Everett CM, Humeniuk KM, Valentin VL (2016). Physician assistant
specialty choice: Distribution, salaries, and comparison with physicians. JAAPA,
29(7), 46-52.
Other (Commentary/Letters/Editorials/Case Reports/Video/Film)
1. Valentin VL (2014). Changes in PA Certification Maintenance. Kentucky Academy of
Physician Assistants newsletter.
2. Valentin VL (2014). Physician Assistant students participating in PA legislation day
at the state capital. Connection Magazine.
3. Valentin VL (2014). Can PAs call Kentucky home? Medical News (22(2), p. 22).
4. Valentin, V, Young, A, Lasley-Bibbs, V (2015). 2015 Kentucky Minority Health Status
Report. Kentucky Department of Public Health.
Video/Film/CD/Web/Podcast
1. Valentin VL (2013). State presidential appointment [Web]. University of Kentucky
web publication. Available: uknow.uky.edu.
2. Valentin VL (2013). President Message [Web]. Kentucky Academy of Physician
Assistant website. Available: http://kentuckypa.org/.
ORAL PRESENTATIONS
Meeting Presentations (Not Published Abstracts and Not Unpublished Posters)
International
2014
Taylor S, Jones M, Schuer KM, Bennett TL, Valentin VL, Jones M.
Faculty Development in Inter-professional Education. US-Thai
Consortium for the Development of Pharmacy Education, Thailand
National
2013
Coombs J, Valentin VL. Is There A Glass Ceiling Over Female
Physician Assistant Educators? American Academy of Physician
Assistants Annual Conference, Washington, DC
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2013
2013
2014
2014
2015
2016
2016
Local/Regional
2012
2013
2013
2014
2014

2014
2014

Skaff KO, Valentin VL. Preparing Faculty to Teach the Oral Cancer
Screen. Physician Assistant Education Association Annual Education
Forum, Workshop, Memphis, TN
Coombs J, Valentin VL. Is There A Glass Ceiling Over Female
Physician Assistant Educators? Physician Assistant Education
Association Annual Education Forum, Memphis, TN
Valentin VL, Bennett TL, Jones J, Hooker R. The Kentucky
Physician Assistant Workforce: 2013. American Academy of
Physician Assistants Annual Conference, Boston, MA
Valentin VL, Bennett TL, Jones J, Hooker R. The Kentucky
Physician Assistant Workforce: 2013. Physician Assistant Education
Association Annual Conference, Philadelphia, PA
White, R, Allman, M, Mealy, K, Valentin, VL, DeRosa, M, Horvath, T.
Fellow Advocacy Session. Physician Assistant Education Association
Annual Conference, Washington, DC.
Valentin, VL, Coombs, J, Jones, J. Where are all the Physician
Assistants in the Beehive State? Physician Assistant Education
Association Annual Conference, Minneapolis, MN.
White, R, Allman, M, Mealy, K, Valentin, VL, DeRosa, M, Horvath, T.
Fellow Advocacy Session. Physician Assistant Education Association
Annual Conference, Minneapolis, MN.
Valentin VL, Powdrill SG. Suturing workshop for Practicing PAs.
Workshop, Kentucky Academy of Physician Assistants 36th Annual
Symposium, Lexington, KY
Valentin VL. Anemia, A Review of Anemia for the PANCE/PANRE
exam. Kentucky Academy of Physician Assistants 37th Annual
Symposium, Lexington, KY
Valentin VL. Patient Center Medical Home-Collaborating Physician
Training Panel. Kentucky Academy of Family Physicians &
Foundation Annual Meeting, Lexington, KY
Valentin VL, Bennett TL, Jones J, Hooker R. The Kentucky
Physician Assistant Workforce: 2013. Public Health Services and
Systems Research Keeneland Conference, Lexington, KY
Valentin VL. Webinar Category 1 CME: Physician Assistants-What
you need to know about the profession and how the new law will
impact their practice. Kentucky Academy of Family Physicians,
Lexington, KY
Coombs J, Valentin VL. Is There A Glass Ceiling Over Female
Physician Assistant Educators? Women's Health Sex and Gender
Research Conference Info Fair, Salt Lake City, Utah, UT
Valentin VL, Bennett TL, Jones J, Hooker R. The Kentucky
Physician Assistant Workforce: 2013. Kentucky Rural Health
Association Annual Conference, Bowling Green, KY

Peer-Reviewed Presentations
National
2016
Christian, J, Chauhan, A, Anthony, L, Nee, J, Huang, B, Durbin, E,
Stewart, R, Valentin, V, Absher, K, Vanderford, N, Arnold, S. Spatiotemporal Analysis of Large Cell Neuroendocrine Lung Cancer in
Kentucky, 1995-2012. Geospatial Approaches to Cancer Control and
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Population Sciences. Bethesda, MD.
OTHER SCHOLARLY ACTIVITY
2015
2016 - Present

Chair Academy, participant, University of Kentucky
• Selected by the Dean for formal training program for future or
present chairs
The effect of faculty and peer interventions on stress levels of
physician assistant students: A multi-site study.
Principle Investigator
Currently investigating
IRB Approval University of Utah 91844

CONTINUING EDUCATION ATTENDED
2016
Remediation: Planning for Success, Physician Assistant Education
Association, Washington, DC.
2016
Leadership I Seminar: Foundations of Leadership, University of Utah
BOARD CERTIFICATIONS
02/01/2008
National Commission on Certification of Physician Assistants,
Certified

Last Updated: 12/26/2016
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